Cochrane Handbook for Systematic Reviews of Interventions
Version 6.4

Technical Supplement to Chapter 4: Searching for and selecting studies
# Table of contents

1 **Sources to search** ........................................................................................................... 4

1.1 Bibliographic databases other than CENTRAL, MEDLINE and Embase ................... 4
    1.1.1 The Cochrane Register of Studies ........................................................................ 4
    1.1.2 National and regional databases ........................................................................ 5
    1.1.3 Subject-specific databases ................................................................................ 6
    1.1.4 Citation indexes ................................................................................................ 7
    1.1.5 Dissertations and theses databases ..................................................................... 10
    1.1.6 Grey literature databases .................................................................................. 12

1.2 Ongoing studies and unpublished data sources: further considerations ............ 15
    1.2.1 Trials registers and trials results registers ......................................................... 15
    1.2.2 Regulatory agency sources and clinical study reports ..................................... 18

1.3 Journals and other non-bibliographic database sources ..................................... 22
    1.3.1 Handsearching ................................................................................................ 22
    1.3.2 Full text journals available electronically ........................................................ 24
    1.3.3 Conference abstracts and proceedings ............................................................. 25
    1.3.4 Other reviews, guidelines and reference lists as sources of studies ................ 26
    1.3.5 General web searching (including search engines/Google Scholar, etc.) ........... 31

1.4 Summary points ........................................................................................................... 34

2 **Planning the search process** ....................................................................................... 35

2.1 Cochrane-wide search initiatives and the Cochrane Centralized Search Service (CSS) .............................................................. 35
    2.1.1 What is in the Cochrane Central Register of Controlled Trials (CENTRAL) from MEDLINE? ........................................... 38
    2.1.2 What is in the Cochrane Central Register of Controlled Trials (CENTRAL) from Embase? ......................................................... 41
    2.1.3 What is in the Cochrane Central Register of Controlled Trials (CENTRAL) from other non-Cochrane sources and handsearching? ............................................................ 43
    2.1.4 What is in the Cochrane Central Register of Controlled Trials (CENTRAL) from Specialized Registers of Cochrane Review Groups and Fields? .................................................. 46

2.2 Searching CENTRAL, MEDLINE, Embase, ClinicalTrials.gov and the ICTRP: specific issues ........................................................................................................... 48
    2.2.1 Searching the Cochrane Central Register of Controlled Trials (CENTRAL): specific issues ................................................................. 48
    2.2.2 Searching MEDLINE and Embase: specific issues ............................................. 49
    2.2.3 Searching ClinicalTrials.gov and WHO ICTRP: special issues .......................... 51

2.3 Summary points ........................................................................................................... 52

3 **Designing search strategies: further considerations** ............................................. 53

3.1 Service providers and search interfaces .................................................................. 53
3.2 Controlled vocabulary and text words ..................................................................... 53
3.2.1 Identifying relevant controlled vocabulary ................................................................. 54
3.2.2 Identifying relevant text words .................................................................................. 56
3.2.3 Text mining for term selection ................................................................................... 56
3.3 Synonyms, related terms, variant spellings, truncation and wildcards ........... 59
3.4 Boolean operators (AND, OR and NOT) ........................................................................ 60
3.5 Proximity operators (NEAR, NEXT and ADJ) ................................................................. 62
3.6 Search filters .................................................................................................................. 66
   3.6.1 The Cochrane Highly Sensitive Search Strategies for identifying randomized trials in MEDLINE ................................................................. 66
   3.6.2 Search filters for identifying randomized trials in Embase ................................... 71
   3.6.3 Search filters for identifying randomized trials in CINAHL versions without full text .. 75
3.7 Demonstration search strategies ................................................................................... 77
3.8 Adapting search strategies across databases/sources and interfaces ............. 79
3.9 Identifying fraudulent studies, other retracted publications, errata and comments: further considerations ................................................................. 81
3.10 Summary points ........................................................................................................ 83
4 Managing references ....................................................................................................... 84
   4.1 Reference management software ............................................................................... 84
   4.2 Which fields to download .......................................................................................... 85
   4.3 De-duplicating references ......................................................................................... 88
   4.4 Summary points ........................................................................................................ 89
5 Supplement information ................................................................................................ 89
6 Acknowledgements ......................................................................................................... 89
7 References ......................................................................................................................... 90
Technical Supplement to Chapter 4: Searching for and selecting studies

Carol Lefebvre, Julie Glanville, Simon Briscoe, Robin Featherstone, Anne Littlewood, Maria-Inti Metzendorf, Anna Noel-Storr, Robin Paynter, Tamara Rader, James Thomas and L. Susan Wieland on behalf of the Cochrane Information Retrieval Methods Group


Throughout this Technical Supplement we refer to the Methodological Expectations of Cochrane Intervention Reviews (MECIR), which are methodological standards to which all Cochrane Protocols, Reviews, and Updates are expected to adhere. More information can be found on these standards at: https://community.cochrane.org/mecir-manual and, with respect to searching for and selecting studies, in Chapter 4 of the Cochrane Handbook for Systematic Review of Interventions.

Further evidence-based information about searching for studies for evidence syntheses can be found on the SuRe Info portal, which is updated twice per year (Isojarvi and Glanville 2021).

1 Sources to search

For discussion of CENTRAL, MEDLINE and Embase as the key database sources to search, please refer to Chapter 4, Section 4.3. For discussion of sources other than CENTRAL, MEDLINE and Embase, please see the sections below. For discussion of some of the specific issues around searching for medical devices, please refer to this recent brief method note (Cooper et al 2022).

1.1 Bibliographic databases other than CENTRAL, MEDLINE and Embase

1.1.1 The Cochrane Register of Studies

The Cochrane Register of Studies (CRS) is a bespoke Cochrane data repository and data management system, primarily used by Cochrane Information Specialists (CISs). The Specialized Registers (registers or databases of trial records on specific topics), maintained by some CISs, are stored and managed within the CRS. As such, it acts as a ‘meta-register’ of all the trials identified by Cochrane but each Cochrane Group has its own section (segment) within the larger database (Cochrane Information Specialist Support Team 2021c). The segment
includes not only the Specialized Register but also all records of studies, or reports of studies, from the included and excluded sections of the Group’s Cochrane Reviews and may also contain other records of interest to the Group. The Cochrane Central Register of Controlled Trials (CENTRAL) is created within the CRS, drawn partly from the references CISs add to their own segments and partly from references to trial reports sourced from other bibliographic databases (e.g. PubMed, Embase and CINAHL). The CRS is the only route available for publication of records in CENTRAL (Cochrane Information Specialist Support Team 2021c).

As a piece of web-based software, the CRS provides tools to manage search activities both for the Cochrane group’s Specialized Register and for individual Cochrane Reviews. CISs are able to import records from external bibliographic databases and other sources into the CRS, de-duplicate them, share them with author teams and track what has been previously retrieved via searching and screened for each review. A further benefit is that trials register records relating to randomized and quasi-randomized studies (currently from ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP)) are searchable from within the CRS. It is possible to store the full text of each bibliographic citation (and any accompanying documents, such as translations) within the CRS as an attachment but this should always be done in compliance with local copyright and database licensing agreements. Records added to the CRS that will be published in CENTRAL are automatically edited in accordance with the Cochrane HarmoniSR guidance, which ensures consistency in record formatting and output (HarmoniSR Working Group 2015). Records from the CRS can be exported in several formats for uploading into Covidence, RevMan or other review management software.

The CRS captures links among references, studies and the Cochrane Reviews within which they appear. This information is drawn from CRS-D, a data repository which sits behind the CRS and includes all CENTRAL records, all included and excluded studies together with ongoing studies, studies awaiting classification and other records collected by CISs in their Specialized Registers. CRS-D has been designed to integrate with RevMan and this linking of data and information back to the reviews will ultimately help review teams find trials more efficiently. For example, CRS-D records can be linked to records in the Reviews Database that powers RevMan, so users can access additional data about the studies that appear in reviews, such as the characteristics of studies, ‘Risk of bias’ tables and, where possible, the extracted data from the study.

The CRS is a mixture of public records, i.e. CENTRAL records and private records for the use of Cochrane staff only. Full access to the content in CRS is available only to designated staff within Cochrane.

1.1.2 National and regional databases
In addition to MEDLINE and Embase, which are generally considered to be the key international general healthcare databases, many countries and regions produce bibliographic databases that focus on the literature produced in those regions and which often include journals and other literature not indexed elsewhere, such as African Index Medicus and LILACs (for Latin

For a list of general healthcare databases, see Appendix.

1.1.3 Subject-specific databases
It is highly desirable, for authors of Cochrane Reviews of interventions, to search appropriate subject-specific bibliographic databases (MECIR C25). Which subject-specific databases to search in addition to CENTRAL, MEDLINE and Embase will be influenced by the topic of the review, access to specific databases and budget considerations.

Most of the main subject-specific databases such as AMED (allied and complementary medicine), CINAHL (nursing and allied health) and APA PsycInfo (psychology and psychiatry) are available only on a subscription or ‘pay-as-you-go’ basis. Access to databases is, therefore, likely to be limited to those databases that are available to the Cochrane Information Specialist at the CRG editorial base or those that are available at the institutions of the review authors. Access arrangements vary according to institution. Review authors should seek advice from a Cochrane Information Specialist, or other medical/healthcare librarian or information specialist about access at their institution.

Although there is overlap in content coverage across Embase, MEDLINE and CENTRAL and subject-specific databases such as AMED, CINAHL and APA PsycInfo (Moseley et al 2009), their performance and facilities vary (Watson and Richardson 1999a, Watson and Richardson 1999b). In addition, a comparison of British Nursing Index and CINAHL shows that even in databases in a specific field such as nursing, each database covers unique journal titles (Briscoe and Cooper 2014). To find qualitative research, CINAHL and APA PsycInfo should be searched in addition to MEDLINE and Embase (Subirana et al 2005, Wright et al 2015, Rogers et al 2017). Even in cases where research indicates low benefit in searching CINAHL, it is still suggested that for subject-specific reviews it should be considered as an option (Beckles et al 2013).

There are also several studies, each based on a single review, and therefore not necessarily generalizable to all reviews in all topics, showing that searching subject specific databases identified additional relevant publications. It is unclear, however, whether these additional publications would change the conclusions of the review. For example, for a review of exercise therapy for cancer patients, searching CancerLit, CINAHL, and APA PsycInfo identified additional records which were not retrieved by MEDLINE searches but searching SPORTDiscus
identified no additional records (Stevinson and Lawlor 2004); for a review of social interventions, only four of the 69 (less than 6%) relevant studies were found by searching databases such as MEDLINE, while about half of the relevant studies were found by searching the Transport database (Ogilvie et al 2005); in an obesity review, searching the Health Management Information Consortium (HMIC) database identified about one fifth of included publications in addition to MEDLINE searches while CINAHL identified no new publications; and in a tuberculosis review, searching CINAHL identified over 5% of the included publications in addition to MEDLINE, whereas the HMIC database identified no additional publications (Levay et al 2015). A review of database sources for a food science systematic review found that the specialist agriculture and food science databases AGRICOLA and FSTA had the highest precision of all databases searched, but did not return any unique citations alongside Academic Science Premier (ASP), CAB Direct, PubMed and Web of Science (Urhan et al 2019).

For a list of subject-specific healthcare databases, see Appendix.

1.1.4 Citation indexes

Citation indexes are bibliographic databases which index citations in addition to the standard bibliographic content. They were originally developed to identify efficiently the reference lists of scholarly authors and the number of times a study or author is cited (Garfield 2007). Citation indexes can also be used creatively to identify studies which are similar to a source study, as it is probable that studies which cite or are cited by a source study will contain similar content.

Searching using a citation index is usually called ‘citation searching’ or ‘citation chasing’ and is further defined as ‘forwards citation searching’ or ‘backwards citation searching’ depending on which direction the citations are searched. Forwards citation searching identifies studies which cite a source study and backwards citation searching identifies studies cited by the source study. Citation indexes are mainly used for forwards citation searching, which is practically impossible to conduct manually, whereas backwards citation searching is relatively easy to conduct manually by consulting reference lists of source studies (see Section 1.3.4). Thus the focus in this section is on forwards citation searching. Citation indexes also facilitate author citation searching which is used to identify studies that are carried out and subsequently published by an author and studies that cite an author.

It is good practice to carry out forwards citation searching on reports of studies that meet the eligibility criteria of a systematic review. Thus forwards citation searching usually takes place after the results of the bibliographic database searches have been screened and a set of potentially includable studies has been identified (Briscoe et al 2020a). Because citation searching is not based on pre-specified terminology it has the potential to retrieve studies that are not retrieved by the keyword-based search strategies that are conducted in bibliographic databases and other resources. This makes citation searching particularly effective in systematic reviews where the search terms are difficult to define, usefully extending to iterative citation searching of citations identified by citation searching (also known as ‘snowballing’) in some reported cases (Booth 2001, Greenhalgh and Peacock 2005, Papaioannou et al 2010, 2011).
Linder et al 2015). Since researchers may selectively cite studies with positive results, forwards citation searching should be used only as an adjunct to other search methods in Cochrane Reviews (Urlings et al 2021).

There are varied findings on the efficiency of forwards citation searching, measured as the labour required to export and screen the results of searches relative to the number of unique relevant studies identified (Wright et al 2014, Hinde and Spackman 2015, Levay et al 2016, Cooper et al 2017b). Most studies, however, which compared the results of forwards citation searching with other search methods found that citation searching identified one or more unique studies which were relevant to the review question (Greenhalgh and Peacock 2005, Papaioannou et al 2010, Wright et al 2014, Hinde and Spackman 2015, Linder et al 2015). Reviews of recently published studies, such as review updates, are less likely to benefit from forwards citation searching than reviews with no historical date limit for includable studies due to the relatively limited time for recent studies to be cited. When conducting a review update, however, searchers should consider carrying out forwards citation searching on the studies included in the original review and on the original review itself.

The two main subscription citation indexes are Web of Science, which was launched in 1964 and is currently provided by Clarivate Analytics, and Scopus, which was launched in 2004 by Elsevier. Google Scholar, which was also launched in 2004, can be used for forwards but not backwards citation searching. Microsoft Academic was relaunched in 2015 (Sinha et al 2015) but closed in December 2021. It could be used for both forward and backward citation searching. A new resource, OpenAlex, was launched in early 2022, and publishes an open API (Application Programming Interface), a downloadable snapshot of all data, and has a website that is currently in ‘alpha’ release at: https://alpha.openalex.org/works but is currently only accessible via API (Application Programming Interface). Functionality appears to be similar to the previous Microsoft Academic website, with forwards and backwards citation searching available, along with a faceted search that supports filtering by multiple domains including geographical location, institution, funder and journal. A summary of these resources is provided below. There are published comparative studies which can be consulted for a more detailed analysis (Kulkarni et al 2009, Wright et al 2014, Levay et al 2016, Cooper et al 2017a).

Web of Science

Web of Science (formerly known as Web of Knowledge), produced by Clarivate Analytics, comprises several databases. The ‘Core Collection’ databases cover the sciences (1900 to date), social sciences (1956 to date), and arts and humanities (1975 to date). The sciences and social sciences collections are divided into journal articles and conference proceedings, which can be searched separately. In total, the Web of Science Core Collection contains approximately 2 billion cited references, 90 million records from more than 20,000 journal titles, and books and conference proceedings going back to 1900. Additional databases are available via the Web of Science platform, also on a subscription basis. Author citation searching is possible in Web of Science but it does not automatically distinguish between
authors with the same name unless they have registered for a uniquely assigned Web of Science ResearcherID.


**Scopus**

Scopus, produced by Elsevier, covers health sciences, life sciences, physical sciences and social sciences. As of May 2023, it contains approximately 85 million records from approximately 25,000 journal titles and approximately 10 million conference abstracts. Records date back to 1788, with approximately 60 million post-1995 records, including references, and approximately 25 million pre-1996 records (Scopus 2022). A unique identification number is automatically assigned to each author in the database which enables it to distinguish between authors with the same names when author citation searching. Errors are still possible, however, as publications are not always assigned correctly to author ID numbers and authors are sometimes erroneously assigned more than one ID number.

https://beta.elsevier.com/products/scopus
https://www.elsevier.com/solutions/scopus/how-scopus-works/content

**Google Scholar**

Google Scholar is a freely available scholarly search engine which uses automated web crawlers to identify and index scholarly references, including published studies and grey literature. Although it can only be used for forwards citation searching, this limitation has little practical significance as backwards citation searching can be easily conducted manually by checking reference lists. The precise number of journals indexed in Google Scholar is not known because it does not use a pre-specified list of journals to populate its content. There is, however, evidence that it has sufficient citation coverage to be used as an alternative to Web of Science or Scopus, if these resources are not available (Wright et al 2014, Levay et al 2016).

A disadvantage of Google Scholar’s automated study identification method is that it produces more duplicate citations than Web of Science, which indexes pre-specified journal content (Haddaway et al 2015). Scopus, which uses a similar indexing method to Web of Science, is also likely to produce fewer duplicates than Google Scholar. A further disadvantage of Google Scholar is that the export features are basic; however, this can be improved by searching it via the freely available Publish or Perish software (Harzing 2007). Finally, Google Scholar limits the number of viewable results to 1000 and does not disclose how the top 1000 results are selected, thus compromising the transparency and reproducibility of search results (Levay et al 2016).

https://scholar.google.com/
OpenAlex

OpenAlex is a tool produced by the non-profit organization OurResearch. In its documentation, OpenAlex is described as a free and open catalogue of the world’s scholarly entities, including scholarly works, authors, journals and other repositories, and institutions, and is probably the world’s largest dataset of its type, with approximately 250 million works as of May 2023. OpenAlex’s first beta data release was in mid-November 2021, positioning itself as a successor to Microsoft Academic, which was retired on 31 December 2021. OpenAlex’s full website is currently in ‘alpha’ (May 2023), supporting faceted search across many fields (e.g. institution, author, geographical location, journal) and the ability to conduct forwards and backwards citation searches.

According to the OpenAlex website, “Using OpenAlex, you can build your own scholarly search engine, recommender service, or knowledge graph. You can help manage research by tracking citation impact, spotting promising new research areas, and identifying and promoting work from underrepresented groups. And you can do research on research itself, in areas like bibliometrics, science and technology studies, and Science of science policy.”

https://openalex.org/about

Web of Science, Scopus, Google Scholar and OpenAlex all provide wide coverage of healthcare journal publications. There are, however, differences in the number of records indexed in each citation index and in the methods used to index records, and there is evidence that these differences affect the number of citations which are identified when citation searching (Kulkarni et al 2009, Wright et al 2014, Rogers et al 2016, Rogers et al 2020). It is not a requirement for Cochrane Reviews, however, to conduct forward citation searching. Review authors and information specialists should consider the time and resources available and the likelihood of identifying unique studies for the review question, when planning whether and how to conduct forwards citation searching.

Further evidence-based information about the value of citation searching for evidence syntheses can be found in the section entitled ‘Value of using different search approaches’ on the SuRe Info portal, which is updated twice per year (Isojarvi and Glanville 2021).

1.1.5 Dissertations and theses databases

It is highly desirable, for authors of Cochrane Reviews of interventions, to search relevant grey literature sources such as reports, dissertations, theses, and conference abstracts (MECIR C28). Dissertations and theses are a subcategory of grey literature, which may report studies of relevance to review authors. Searching for academic research published only in the form of dissertations or theses may be important for countering possible publication bias but it can be time consuming and in some cases yield few included studies (van Driel et al 2009). In some areas of health care, searching for and retrieving studies published only as dissertations or theses has been shown to have a limited influence on the conclusions of a review (Vickers and Smith 2000, Royle et al 2005). In other areas of health care, however, it is essential to broaden
the search to include trials published in more diverse sources, for example in oncology and in complementary medicine (Egger et al 2003). In a study of 129 systematic reviews from three Cochrane Review Groups (the Acute Respiratory Infections Group, the Infectious Diseases Group and the Developmental, Psychosocial and Learning Problems Group) there was wide variation in the retrieval and inclusion of dissertations and theses (Hartling et al 2017). It is possible that a study which would affect the conclusions would be missed if the search is not comprehensive enough to include searches for unpublished trials and those reported only in dissertations and theses (Egger et al 2003). The failure to search for unpublished trials and those published only in dissertations and theses, may lead to biased results in some reviews (Ziai et al 2017). Dissertations and theses are not normally indexed in general bibliographic databases such as MEDLINE or Embase, but there are exceptions, such as CINAHL, which indexes nursing, physiotherapy and occupational health dissertations and theses and APA PsycInfo, which indexes dissertations and theses in psychiatry and psychology.

To identify relevant studies published in dissertations or theses it is advisable to search specific dissertation sources:

- The US-based Center for Research Libraries (CRL) is an international consortium of university, college, and independent research libraries (http://catalog.crl.edu/search~S4)

- The LILACS database includes some dissertations and theses from Latin American and Caribbean countries (http://lilacs.bvsalud.org/en/)

- Open Access Theses and Dissertations (OATD) includes dissertations and theses that are free to access and read online from participating universities from around the world (https://oatd.org/). OATD has shown a high level of success at retrieving electronic dissertations and theses (88.5% retrieved) compared to Google Scholar (76% retrieved) and other search engines (Loan et al 2022).

- ProQuest Dissertations and Theses Global (PQDT) is the best-known commercial database for searching dissertations and theses. Access to PQDT is by subscription. As of May 2023, ProQuest Dissertations and Theses Global database indexes more than 5 million doctoral dissertations and Master’s theses from around the world with full text available for approximately 3 million of these records (https://about.proquest.com/en/products-services/pqdtglobal).

Other sources of dissertations and theses include the catalogues and resources produced by national libraries and research centres, for example:

- Australian dissertations and theses are searchable via the National Library of Australia’s Trove service (http://trove.nla.gov.au/)

- DART-Europe is a partnership of several research libraries and library consortia which provides global access to European research dissertations and theses via a portal. A list of
institutions, national libraries and consortia who contribute to the portal can be found here: (https://www.dart-europe.org/)

- Deutsche Nationalbibliothek (German National Library) provides access to electronic versions of dissertations and theses since 1998 (but now also included in DART-Europe – see above) https://www.dnb.de/EN/Professionell/Services/Dissonline/dissonline_node.html).

- The Networked Digital Library of Theses and Dissertations (NDLTD) is an international organization dedicated to promoting the adoption, creation, use, dissemination, and preservation of electronic dissertations and theses. (http://search.ndltd.org/)

- Swedish University Dissertations / Dissertations.se offers dissertations and theses in English, about half of which are available to download (http://www.dissertations.se/)

- Theses Canada provides access to the National Library of Canada's records of PhD and Master's dissertations and theses from Canadian universities (https://library-archives.canada.ca/eng/services/services-libraries/theses/Pages/theses-canada.aspx).

Other countries also offer access to dissertations and theses in their national languages.

Whenever possible, review authors should attempt to include all relevant studies of acceptable quality, irrespective of the type of publication, since the inclusion of these may have an impact in situations where there are few relevant studies, or where there may be vested interests in the published literature (Hartling et al 2017, Greyson et al 2019). The inclusion of unpublished trials and those published only in dissertations and theses should increase precision, generalizability and applicability of findings (Egger et al 2003). In the interest of feasibility, review authors should assess their research questions and topic area, and seek advice from content experts when selecting dissertation and theses databases to search. Review authors should consult a Cochrane Information Specialist, local library or university for information about dissertations and theses databases in their country or region.

1.1.6 Grey literature databases
As stated above, it is highly desirable, for authors of Cochrane Reviews of interventions, to search relevant grey literature sources such as reports, dissertations, theses, and conference abstracts (MECIR C28).

Grey literature was defined at GL3, the Third International Conference on Grey Literature on 13 November 1997 in Luxembourg as “that which is produced on all levels of government, academics, business and industry in print and electronic formats, but which is not controlled by commercial publishers” (Farace and Frantzen 1997). On 6 December 2004, at GL6, the Sixth Conference in New York City, a clarification was added: grey literature is “... not controlled by commercial publishers, i.e. where publishing is not the primary activity of the producing body
In a 2017 audit of 203 systematic reviews published in high-impact factor general medical journals in 2013, 64% described an attempt to search for unpublished studies together with those published only in dissertations and theses. The audit showed that reviews published in the Cochrane Database of Systematic Reviews were significantly more likely to include a search for grey literature than those published in standard journals (Ziai et al. 2017). A Cochrane Methodology Review indicated that trials published in journal articles showed an overall greater treatment effect than trials published in grey literature (Hopewell et al. 2007a). Although failure to identify trials reported in conference proceedings and other grey literature might affect the results of a systematic review (Hopewell et al. 2007a), a subsequent systematic review showed that this was only the case in a minority of reviews (Schmucker et al. 2017). Since the impact of excluding unpublished data and data published only in grey literature is unclear, review authors should consider the time and effort spent when planning the grey-literature portion of the search.

Grey literature’s diverse formats and audiences can present a significant challenge in a systematic search for evidence. Locating grey literature can often be challenging, requiring librarians and information specialists to use several databases from various providers or websites, some of which they may not be familiar with (Saleh et al. 2014, Haddaway and Bayliss 2015). There are many characteristics of grey literature that make it difficult to search systematically. Further, there is no ‘gold standard’ for rigorous systematic grey literature search methods and few resources on how to conduct this type of search (Godin et al. 2015, Paez 2017). One challenge of searching the grey literature is managing an abundance of material. Often, there are many sources to search but some review authors of very broad or cross-disciplinary topics may find it necessary to impose some limits on the extent of their grey literature searching by considering what is feasible within limited time and resources (Mahood et al. 2014). For example, since nearly half of the citations found in reviews of new and emerging non-drug technologies are published in grey literature, searchers should consider focusing their efforts on search engines and aggregator sites to increase feasibility (Farrah and Mierzwinski-Urban 2019). Google Scholar can help locate a large volume of grey literature and specific, known studies, however, it should not be used as the only resource for systematic review searches (Haddaway et al. 2015). The types of grey literature that are useful in specific reviews may depend on the research question and researchers may decide to tailor the search to the question (Levay et al. 2015). For example, academic research published only in grey literature may be important for countering possible publication bias and can be targeted via specific repositories for preprints, theses and funding registries. Alternatively, if the research question is related to implementation or if the researchers are interested in material to support their implications for practice section, then organizational reports, government documents and monitoring and evaluation reports, might be important for ensuring the search is extensive and fit for purpose (Haddaway and Bayliss 2015).

Careful documentation throughout the search process and reporting of search methods will demonstrate that efforts have been made to be comprehensive and will help in making the grey literature searching as reproducible as possible (Stansfield et al. 2016).
The following resources can help authors plan a manageable and thorough approach to searching the grey literature for their topic.

- The Canadian Agency for Drugs and Technologies in Health (CADTH) (https://greymatters.cadth.ca/) publishes a resource entitled ‘Grey Matters: a tool for searching health-related grey literature’, which lists a considerable number of grey literature sources together with annotations about their content as well as search hints and tips.

- The Health-Related Grey Literature guide (http://www.greylitguides.com/health-related-grey-lit/) is a source of health-related grey literature, organized geographically. It is part of Grey Literature Guides, a directory of research guides, online courses and webinars. The website provides links to a selection of existing English language educational and training resources devoted to grey literature worldwide. It is maintained by GreyNet’s Grey Literature Education and Training Committee and revised annually.

- The Health Management Information Consortium (HMIC) Database (https://www.kingsfund.org.uk/consultancy-support/library-services; https://www.wolterskluwer.com/en/solutions/ovid/hmic-database-99) contains records from the Library and Information Services department of the UK Department of Health (DH Data) and the King’s Fund Information and Library Service. It includes all UK Department of Health publications including circulars and press releases. The King’s Fund is an independent health charity that works to develop and improve management of health and social care services. The database is considered to be a good source of grey literature on topics such as health and community care management, organizational development, inequalities in health, user involvement, and race and health. The King’s Fund Information and Library Service records can be searched free of charge via the link above. The UK Department of Health data can be searched on subscription only.

- The US National Technical Information Service (NTIS) (https://www.ntis.gov) provides access to the results of both US and non-US government-sponsored research and can provide the full text of the technical report for most of the results retrieved. NTIS is free of charge on the Internet and goes back to 1964. For access to technical reports see the National Technical Reports Library at https://ntrl.ntis.gov/NTRL/; for access to the NTIS Bibliographic Database, log in is required.

- OpenGrey was a multidisciplinary European grey literature database, covering science, technology, biomedical science, economics, social science and humanities. Each record had an English title and/or English keywords. Some records included an English abstract (starting in 1997). The database included technical or research reports, doctoral dissertations, conference presentations, official publications, and other types of grey literature. Information was also provided regarding how to access the documents included in the database. Access to this database via Inist-CNRS ceased in November 2020, but a searchable archived version is available from the Data Archiving and

- APA PsycExtra (http://www.apa.org/pubs/databases/psycextra/) is a companion database to APA PsycInfo in psychology, behavioural science and health. It includes references from newsletters, magazines, newspapers, technical and annual reports, government reports and consumer brochures. APA PsycExtra is different from APA PsycInfo (https://www.apa.org/pubs/databases/psycinfo/index) in its format, because it includes abstracts and citations plus full text for a major portion of the records. There is no coverage overlap between APA PsycExtra and APA PsycInfo.

Conference abstracts are a particularly important source of grey literature and are further covered in Section 1.3.3. Dissertations and theses are covered above in Section 1.1.5.

1.2 Ongoing studies and unpublished data sources: further considerations

This section should be read in conjunction with Chapter 4, Sections 4.3.2 to 4.3.4.

1.2.1 Trials registers and trials results registers

It is mandatory, for authors of Cochrane Reviews of interventions, to search trials registers and repositories of results, where relevant to the topic, through ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) portal and other sources as appropriate (MECIR C27) (see Chapter 4, Section 4.3.3). Although ClinicalTrials.gov is included as one of the registers within the WHO ICTRP portal, it is recommended that both ClinicalTrials.gov and the ICTRP portal should be searched separately, from within their own interfaces, due to additional features in ClinicalTrials.gov (Glanville et al 2014) (see below). The extent to which this might still be the case with the new ICTRP interface released in its final version in June 2021 and the changes being made under the ClinicalTrials.gov Modernization programme remains to be ascertained. Therefore, the current guidance that it is not sufficient to search the ICTRP alone still stands, pending further research. It is recognized, however, that the search interfaces of many of these trials registers and portals is suboptimal, resulting in challenges for those searching them (Cooper et al 2021a).

Several initiatives have led to the development of and recommendations to search trials registers. The International Committee of Medical Journal Editors (ICMJE) requires prospective registration of studies for subsequent publication in their journals, and there is a legal requirement that the results of certain studies must be posted within a given timeframe. Several studies have shown, however, that adherence to these requirements is mixed (Gill 2012, Huser and Cimino 2013a, Huser and Cimino 2013b, Jones et al 2013, Anderson et al 2015, Dal-Re et al 2016, Goldacre et al 2018, Jorgensen et al 2018, Chen et al 2022) and that results posted on ClinicalTrials.gov show discordance when compared with results published in journal articles (Gandhi et al 2011, Earley et al 2013, Hannink et al 2013, Becker et al 2014, Hartung et al 2014, De Oliveira et al 2015) or both of the above (Jones and Platts-Mills 2012, Adam et al 2018). A recent study indicated that, despite the initiatives mentioned above, many
systematic reviews in the field of critical care failed to include searches of trials registers (Greiner et al 2021). A recent analysis of ClinicalTrials.gov registration data from 2000-2020 showed that the number and percentage of registered trials reporting results had increased since the inception of ClinicalTrials.gov, peaking in 2007 (n=2840, 36%) when the ClinicalTrials.gov results database was launched, compared to previous years ranging from 8.7 to 24.5% of trials with posted results (Gresham et al 2022). The time to report results had also improved over time, decreasing from a median of 29 months in 2007, when the result database was launched, to 12 months in 2015, and 10 months in 2020. A recent study, however, highlighted failings in the then current implementation of ClinicalTrials.gov (the ‘classic version’) including the lack of MeSH terms for interventions and outcomes, the fact that synonyms in searches could not be toggled off and that inclusion criteria and exclusion criteria were in the same field (Miron et al 2020). Further guidance on searching trials registers and related portals can be found in a recent article (Hunter et al 2022).

ClinicalTrials.gov

In February 2000, the US National Library of Medicine (NLM) launched ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home). ClinicalTrials.gov was created as a result of the Food and Drug Administration Modernization Act of 1997 (FDAMA). FDAMA required the US Department of Health and Human Services, through the US National Institutes of Health (NIH), to establish a register of clinical trials information for both (US) federally and privately funded trials conducted under ‘investigational new drug’ applications to test the effectiveness of experimental drugs for “serious or life-threatening diseases or conditions”. The ClinicalTrials.gov registration requirements were expanded after the US Congress passed the FDA Amendments Act of 2007 (FDAAA). Section 801 of FDAAA (FDAAA 801) required more types of trials to be registered and additional trial registration information to be submitted. The law also required the submission of results for certain trials. This led to the expansion of ClinicalTrials.gov to include information on study participants and a summary of study outcomes, including adverse events. Results have been made available since September 2008. Further legislation has expanded the coverage of results in ClinicalTrials.gov, which now serves as a major international register including more than 450,000 study records from over 200 countries (as of May 2023). Searches of ClinicalTrials.gov can be limited to studies which include results by selecting ‘With results’ under the ‘Study Results’ filter under More Filters on the home page of the ‘modernized’ ClinicalTrials.gov site, which became the primary site for ClinicalTrials.gov in June 2023. Research published in 2014 showed that the most reliable way of searching ClinicalTrials.gov was to conduct a highly sensitive ‘single concept’ search in the basic interface of ClinicalTrials.gov (Glanville et al 2014). This study also suggested that use of the advanced interface seemed to improve precision without loss of sensitivity and this interface might be preferred when large numbers of search results were anticipated. As mentioned above, the new ICTRP interface released in its final version in June 2021 and the changes being made under the ClinicalTrials.gov Modernization programme remain to be ascertained. The ‘classic’ ClinicalTrials.gov site will be available until 2024 and the help files
listed below relate to the ‘classic’ site. The US NLM has not yet (July 2023) released any help files for the ‘modernized’ site.

Search help for the ClinicalTrials.gov ‘classic’ site is available from the following links:

How to Use Basic Search
https://clinicaltrials.gov/ct2/help/how-find/basic

How to Use Advanced Search
https://clinicaltrials.gov/ct2/help/how-find/advanced

How to Read a Study Record
https://clinicaltrials.gov/ct2/help/how-read-study

How to Use Search Results
https://clinicaltrials.gov/ct2/help/how-use-search-results

The World Health Organization International Clinical Trials Registry Platform search portal (WHO ICTRP)
In May 2007, the World Health Organization (WHO) launched the International Clinical Trials Registry Platform (ICTRP) search portal (https://trialsearch.who.int/), to search across a range of trials registers, similar to the initiative launched some years earlier by Current Controlled Trials with their ‘metaRegister’ (which has ceased publication). Currently (May 2023), the WHO portal searches across 20 registers (including ClinicalTrials.gov but note the guidance above regarding searching ClinicalTrials.gov separately through the ClinicalTrials.gov interface). Research has shown that the most reliable way of searching the ICTRP was to conduct a highly sensitive ‘single concept’ search in the ICTRP basic interface (Glanville et al 2014). This study suggested that use of the ICTRP advanced interface might be problematic because of reductions in sensitivity. The extent to which this might still be the case with the new ICTRP interface, released in its final version in June 2021, remains to be ascertained.

Search help for the ICTRP is available from the following link:
https://www.who.int/clinical-trials-registry-platform/the-ictrp-search-portal/search-tips

Other trials registers and trials register resources
In May 2021, the UK National Institute for Health Research (NIHR) Innovation Observatory launched ScanMedicine (https://scanmedicine.com/), a resource which draws records from 11 national and international trials register resources with information on drugs, devices and diagnostics together with digital applications approved by the FDA, enabling searches back to
HSRProj (Health Services Research Projects in Progress) provided information about ongoing health services research and public health projects. It contained descriptions of research in progress funded by US federal and private grants and contracts for use by policy makers, managers, clinicians and other decision makers. It provided access to information about health services research in progress before, and irrespective of whether, results were available in a published form. In June 2021, the US National Library of Medicine (NLM) announced that they would discontinue HSRProj from September 2021. HSRProj data are now archived and downloadable as below.

[https://healthdata.gov/dataset/Health-Services-Research-Projects-in-Progress-HSRP/u8mi-83iu/data](https://healthdata.gov/dataset/Health-Services-Research-Projects-in-Progress-HSRP/u8mi-83iu/data)


Many countries and regions maintain trials and/or trials results registers. There are also many condition-specific trials registers, especially in the field of cancer, which are too numerous to list. Some pharmaceutical companies make available information about their clinical trials through their own websites, either instead of or in addition to the information they make available through national or international registers or websites. Additionally, there are commercially produced trials registers, which are available on a subscription basis.

Clinical Trial Results ([https://clinicaltrialresults.org/](https://clinicaltrialresults.org/)) is a website that hosts slide and video presentations from clinical trialists, especially in the field of cardiology but also other specialties, reporting the results of clinical trials.

Further listings of international, national, regional, subject-specific and industry trials registers, together with guidance on how to search them can be found on a website developed in 2009 and since then updated by two of the co-authors of this chapter (JG and CL) entitled Finding clinical trials, research registers and research results ([https://sites.google.com/a/york.ac.uk/yhectrialsregisters/](https://sites.google.com/a/york.ac.uk/yhectrialsregisters/)).

### 1.2.2 Regulatory agency sources and clinical study reports

Regulatory agencies serve as sources of trial records by producing trials registers and also as a source of clinical study reports and related documents. Both these types of regulatory information are discussed below.

**The EU Clinical Trials Register (EU CTR)**

The EU CTR contains protocol and results information for interventional clinical trials on medicines, conducted in the European Union (EU) and the European Economic Area (EEA), which started after 1 May 2004. It enables searching for information in the EudraCT database, used by national medicines regulators for data related to clinical trial protocols. Results data
are extracted from data entered by the sponsors into EudraCT. The EU CTR has been a ‘primary registry’ in the ICTRP since September 2011 but in the absence of any evidence to the contrary, it is recommended that searches of the EU CTR should be carried out within the EU CTR and not solely within the ICTRP (in line with the advice above regarding searching ClinicalTrials.gov). The register currently (May 2023) contains information about approximately 60,000 clinical trials. Searches can be limited to ‘Trials with results’ under the ‘Results Status’ option. Records can be selected individually for downloading or can be downloaded one page at a time (maximum 20 records). The posting of clinical trial summary results became mandatory in 2014. There is no information on non-interventional clinical trials (e.g. observational studies), clinical trials for surgical procedures, medical devices or psychotherapeutic procedures.

https://www.clinicaltrialsregister.eu/ctr-search/search

https://www.clinicaltrialsregister.eu/about.html

The European Clinical Trials Information Service/the EU Clinical Trials database

https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en

The European Union (EU) has launched a new database called the EU Clinical Trials Database as part of a newly-established EU Clinical Trials Information System (CTIS). From 31 January 2023, all initial clinical trial applications in the EU must be submitted via the CTIS. The CTIS includes the EU Clinical Trials Database as a public, searchable database. By 31 January 2025, all ongoing trials that were approved under the EU Clinical Trials Directive will be governed by the new Regulation and will have to be transitioned to CTIS. The website currently contains limited information on clinical trials entered since its launch, in a 12-month transition phase, on 31 January 2022 (c. 180 as of 31 May 2023). It will gradually contain more information as clinical trial sponsors and EU/EEA regulators use it to initiate and oversee clinical trials in the EU and the EEA. Search tips and guidance are available from: https://euclinicaltrials.eu/search-tips-and-guidance/?lang=en.

https://euclinicaltrials.eu/about-this-website/?lang=en


For information about clinical trials initiated before 31 January 2022 and those initiated during the transition phase between 31 January 2022 and 31 January 2023, it will be necessary to continue using the EU Clinical Trials Register (EU CTR) described above.

The European Database on Medical Devices (EUDAMED) – under development

The EU is in the process of developing and introducing a database for medical devices, known as EUDAMED. It has been established as part of Regulation (EU) 2017/745 on medical devices
and Regulation (EU) 2017/746 on in vitro diagnosis medical devices. It is expected that the database will be fully functioning and mandatory by 2026.


Drugs@FDA and medical device information from the FDA
Drugs@FDA is hosted by the US Food and Drug Administration (FDA) and provides information about most of the drugs approved in the US since 1939. For those approved more recently (from 1998), there is often a ‘Review’, which is an internal review containing the scientific analyses that provided the basis for approval of the new drug. In 2012, new search options were introduced, enabling search strategies to be saved and re-run and results to be downloaded to a spreadsheet (Goldacre et al 2017).

www.fda.gov/drugsatfda

https://www.accessdata.fda.gov/scripts/cder/daf/

https://www.fda.gov/drugs/drug-approvals-and-databases/about-drugsfda

Information on how to search Drugs@FDA is available from the Frequently Asked Questions pages at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=faq.page

The FDA also makes information about devices, including several medical device databases, available on its website:

https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/medical-device-databases

Clinical study reports
Clinical study reports (CSRs) are reports of clinical trials, which provide detailed information on the methods and results of clinical trials submitted in support of marketing authorization applications. Cochrane funded a project under the Methods Innovation Funding programme to draft interim guidance to help Cochrane Review authors decide whether to include data from clinical study reports (CSRs) and other regulatory documents in a Cochrane Review (Hodkinson et al 2018, Jefferson et al 2018).

A Clinical Study Reports Working Group has been established in Cochrane to take this work forward and to consider how CSRs might be used in Cochrane Reviews in future. To date, only one Cochrane Review is based solely on CSRs, that is the 2014 review update on neuraminidase inhibitors for preventing and treating influenza in healthy adults and children (Jefferson et al 2014).
Although pharmaceutical companies are obliged to submit details of all clinical trials within their clinical study reports, studies have found that this is not always the case (Boesen et al 2022). A recent study compared the availability of CSRs from Canada Health, the EMA and the FDA, including a comparison of the data made available by the various agencies and the time taken to make this information available (Egilman et al 2021).

In late 2010, the European Medicines Agency (EMA) began releasing CSRs (on request) under their Policy 0043. In October 2016, they led the field by beginning to release CSRs under their Policy 0070. The policy applies only to documents received since 1 January 2015. CSRs are available for approximately 200 products (as of April 2023) (https://clinicaldata.ema.europa.eu/web/cdp/background).


https://clinicaldata.ema.europa.eu/web/cdp/search

In December 2018, the Agency suspended the publication of clinical data as a result of the implementation of the third phase of the EMA’s business continuity plan (i.e. Brexit and the resulting transfer of the EMA offices from London to Amsterdam) and it remains suspended due to ongoing business continuity linked to the COVID-19 pandemic (except for COVID-19 trials). The EMA is publishing clinical data for COVID-19 medicines in line with its exceptional transparency measures for treatments and vaccines for COVID-19. As noted above, as of April 2023, there were approximately 200 CSR records with publication dates from October 2016 to December 2018, except COVID-19 studies which were up to date.

In order to download the full CSR documents, it is necessary to register for use “for academic and other non-commercial research purposes” and to provide an email address and a place of address in the European Union, or provide details of a third party, resident or domiciled in the European Union, who will be considered to be the user.

https://clinicaldata.ema.europa.eu/web/cdp/termsofuse

Clinical study reports from the Food and Drug Administration (FDA)

The FDA does not currently routinely provide access to CSRs, only their own internal reviews, as noted above. In January 2018, they announced a voluntary pilot programme to disclose up to nine recently approved drug applications, limited to CSRs for the key ‘pivotal’ trials that underpin drug approval (Doshi 2018). They succeeded, however, in only covering one drug application within this pilot programme, which has now ended. A public consultation of this pilot project (which included only one CSR) was undertaken in August 2019.

The FDA subsequently announced that “...increasing international harmonization efforts to share clinical study reports is a long-term goal”.


Clinical study reports from Health Canada
In April 2019 Health Canada announced that it was starting to make clinical information (i.e. CSRs) about drugs and devices publicly available on its website (https://clinical-information.canada.ca/search/ci-rc) (Lexchin et al 2019). As of May 2023, information was available for approximately 400 drug records and 100 medical device records.

Other related information from other regulatory agencies
Australia: the Therapeutic Goods Administration (Australia) (TGA) provides access to Australian Public Assessment Reports for prescription medicines (AusPARs) but not the full CSRs – approximately 1,000 records as of 15 Apr 2023)


Japan: The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) also provides access to its own internal reviews of approved drugs and medical devices but not the original CSRs. These can be found in the Reviews section of its website at:

https://www.pmda.go.jp/english/review-services/reviews/0001.html
https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html

For more information on drug and device information from regulatory sources see: Restoring Invisible and Abandoned Trials (RIAT) initiative website:

https://restoringtrials.org/regulatory-resources/

1.3 Journals and other non-bibliographic database sources

1.3.1 Handsearching
Handsearching involves a manual page-by-page examination of the entire contents of a journal issue or conference proceedings to identify all eligible reports of trials (for discussion of ‘handsearching’ full-text journals available electronically, see Section 1.3.2). In journals, reports of trials may appear in articles, abstracts, news columns, editorials, letters or other text. Handsearching healthcare journals and conference proceedings can be a useful adjunct to searching electronic databases for at least two reasons: 1) not all trial reports are included in electronic bibliographic databases, and 2) even when they are included, they may not contain relevant search terms in the titles or abstracts or be indexed with terms that allow them to be easily identified as trials (Dickersin et al 1994). It should be noted, however, that
handsearching is not a requirement for all Cochrane Reviews and review authors should seek advice from a Cochrane Information Specialist, or other medical/healthcare librarian or information specialist with respect to whether handsearching might be valuable for their review, and if so, what to search and how (Cochrane Information Specialist Support Team 2021a). Methods of identifying which journals to handsearch and evidence around the usefulness of handsearching are summarized in an overview of published guidance (Cooper et al 2017a). Each journal year or conference proceeding that is to be handsearched should be searched thoroughly and competently by a well-trained handsearcher, ideally for all reports of trials, irrespective of topic, so that once it has been handsearched it will not need to be searched again. A Cochrane Methodology Review found that a combination of handsearching and electronic searching is necessary for full identification of relevant reports published in journals, even for those that are indexed in MEDLINE (Hopewell et al 2007b). This was especially the case for articles published before 1991 when there was no indexing term for randomized trials in MEDLINE and for those articles that are in parts of journals (such as supplements and conference abstracts) which are not routinely indexed in databases such as MEDLINE. A review (Richards 2008) found that handsearching was valuable for finding trials reported in abstracts or letters, or in languages other than English. We note that Embase is now a good source of conference abstracts (see Section 1.3.3).

To facilitate the identification of all published trials, Cochrane has organized extensive handsearching efforts. Over 3000 journals have been searched within Cochrane. The list of journals that have already been handsearched is no longer being updated, but a record of journals searched, with the dates covered by the search is available via the Handsearched Journals tab in the Cochrane Register of Studies Online at crso.cochrane.org, (Cochrane Account login required). Citations for the handsearched records are available in CENTRAL.

With respect to handsearching conference abstracts or proceedings, this should still be considered for finding studies which may be published only as conference abstracts. Many conference proceedings are now included within Embase, but searches of Embase will not necessarily find all the trial records in a conference issue (Stovold and Hansen 2011, Cooper et al 2020). Coverage of specific conferences of interest can be ascertained by checking the list of conferences indexed in Embase: https://beta.elsevier.com/products/embase/content?trial=true.

Cochrane groups and authors can prioritize handsearching based on where they expect to identify the most trial reports. This prioritization can be informed by searching CENTRAL, MEDLINE and Embase in a topic area and identifying which journals appear to be associated with the most retrieved citations. Preliminary evidence suggests that most of the journals with a high yield of trial reports are indexed in MEDLINE (Dickersin et al 2002) but this may reflect the fact that Cochrane contributors have concentrated early efforts on searching these journals. Therefore, journals not indexed in MEDLINE or Embase should also be considered for handsearching. Research into handsearching journals in a range of languages suggests that handsearching journals published in languages other than English is still helpful for identifying
trials which have not been retrieved by database searches (Blumle and Antes 2005, Fedorowicz et al 2005, Al-Hajeri et al 2006, Nasser and Al Hajeri 2006, Chibuzor and Meremikwu 2009). The value of handsearching may vary from topic to topic. In physiotherapy and respiratory disease, studies have found handsearching yielded additional studies (Stovold and Hansen 2011, Craane et al 2012). Identifying studies of handsearching in specific disease areas may help to inform decisions around handsearching.

The Cochrane Training Manual for Handsearchers is available on the Cochrane Information Retrieval Methods Group Website: http://methods.cochrane.org/irmg/resources.

Handsearching may be facilitated by tools such as Paperfetcher or programs written in R or Python, which may automate the record collection process (Pallath and Zhang 2023).

**1.3.2 Full text journals available electronically**
The full text of many journals is available electronically on the Internet. Access may be partially or wholly on a subscription basis or free of charge. In addition to providing a convenient method for retrieving the full article of already identified records, full-text journals can also be searched electronically, depending on the search interface, by entering relevant keywords in a similar way to searching for records in a bibliographic database. Electronic journals can also be 'handsearched' in a similar manner to that advocated for journals in print form, in that each screen or 'page' can be checked for possibly relevant studies in the same way as handsearching a print journal (see Section 1.3.1). When reporting handsearching, it is important to specify whether the full text of a journal has been searched electronically or using the print version. Some journals omit sections of the print version, for example letters, from the electronic version and some include supplementary information such as extra articles in the electronic format only.

Most academic institutions subscribe to a wide range of electronic journals and these are therefore available free of charge at the point of use to members of those institutions. Review authors should seek advice about electronic journal access from the library service at their institution. Some professional organizations provide access to a range of journals as part of their membership package. In some countries similar arrangements exist for health service employees through national licences.

Several international initiatives provide free or low-cost online access to full-text journals over the Internet. The Health InterNetwork Access to Research Initiative (HINARI) programme, set up by the World Health Organization (WHO) together with major publishers and now part of the Research4Life programme (R4L), provides access to a wide range of resources, including journals, for healthcare professionals in local, not-for-profit institutions in more than 120 countries, areas and territories. The International Network for the Availability of Scientific Publications (INASP) also provides access to a wide range of journals (and databases). Electronic Information for Libraries (EIFL) is a similar initiative based on library consortia to support affordable licensing of journals and other sources in over 50 developing and transition countries in Africa, Asia, Europe and Latin America.
A local electronic or print copy of any possibly relevant article as well as its online supplementary material found in a subscription journal should be taken and filed (within copyright legislation), as the subscription to that journal may cease. The same applies to electronic journals available free of charge, as the circumstances around availability of specific journals might change. We have not been able to identify any research evidence regarding searching full-text journals available electronically. Review authors are not routinely expected to search full-text journals available electronically for their reviews, but they should seek advice from a Cochrane Information Specialist, or other medical/healthcare librarian or information specialist, as to whether, in their particular case, this might be beneficial.

**1.3.3 Conference abstracts and proceedings**

It is highly desirable, for authors of all Cochrane Reviews of interventions, to search relevant databases of conference abstracts (MECIR C28). Some bibliographic databases do include conference abstracts. While MEDLINE does index some conference abstracts and proceedings (to identify these, use Congress, Meeting Abstracts and Overall as the Publication Types), Embase is a better source with about 4.5 million conference abstracts from about 12,000 conferences (as of 2023) [https://beta.elsevier.com/products/embase/content?trial=true](https://beta.elsevier.com/products/embase/content?trial=true). As noted above, Elsevier provides a list of conferences it indexes in Embase: [https://beta.elsevier.com/products/embase/content?trial=true](https://beta.elsevier.com/products/embase/content?trial=true). As a result of Cochrane’s Embase project (see Section 2.1.2), conference abstracts that are indexed in Embase and are reports of RCTs are now being included in CENTRAL. Other conference abstracts resources include the Web of Science Conference Proceedings Citation Index [https://clarivate.com/products/scientific-and-academic-research/research-discovery-and-workflow-solutions/web-of-science/web-of-science-core-collection/conference-proceedings-citation-index/](https://clarivate.com/products/scientific-and-academic-research/research-discovery-and-workflow-solutions/web-of-science/web-of-science-core-collection/conference-proceedings-citation-index/) and Northern Light Life Science Conference Abstracts [https://northernlight.com/life-sciences-conference-abstracts/](https://northernlight.com/life-sciences-conference-abstracts/). Additionally, many conference proceedings are published as journal supplements or as proceedings on the website of the conference or the affiliated organization. A Cochrane Methodology Review found that trials with positive results tended to be published in approximately four to five years whereas trials with null or negative results were published after about six to eight years ([Hopewell et al. 2007c](https://hopewell.et.al.2007c)) and not all conference presentations are published or indexed ([Slobogean et al. 2009](https://slobogean.et.al.2009)). Over one-half of trials reported in conference abstracts never reach full publication ([Diezel et al. 1999, Scherer et al. 2018](https://diezel.et.al.1999, https://scherer.et.al.2018)) and those that are eventually published in full have been shown to have results that are systematically different from those that are never published in full ([Scherer et al. 2018](https://scherer.et.al.2018)). In addition, conference abstracts/proceedings are a good source to track disagreements between the original abstract and the full report of studies (known as reporting bias) ([Chokkalingam et al. 1998, Pitkin et al. 1999](https://chokkalingam.et.al.1998, https://pitkin.et.al.1999)). Trials with positive findings are more likely to be published than those which do not have positive findings (known as publication bias) ([Salami and Alkayed 2013](https://salami.and.alkayed.2013)). It is, therefore, important to try to identify possibly relevant studies reported in conference abstracts through specialist database sources and by searching those abstracts that are made available on the Internet, on CD-ROM/DVD or in print form. Controversies around the usefulness of searching for conference abstracts
include: whether the reported information is dependable; poor CONSORT abstract reporting quality; and the high screening burden with likely few includable studies (Schmucker et al 2017, Scherer and Saldanha 2019, Hackenbroich et al 2022).

1.3.4 Other reviews, guidelines and reference lists as sources of studies

It is highly desirable, for authors of Cochrane Reviews of interventions, to search within previous reviews on the same topic (MECIR C29) and it is mandatory, for authors of Cochrane Reviews of interventions, to check reference lists of included studies and any relevant systematic reviews identified (MECIR C30). Reviews can provide relevant studies and references, and may also provide information about the search strategy used, which may inform the current review (Hunt and McKibbon 1997, Glanville and Lefebvre 2000). Copies of previously published reviews on, or relevant to, the topic of interest should be obtained and checked for references to the included (and excluded) studies. Various sources for identifying previously published reviews are described below.

As well as the Cochrane Database of Systematic Reviews (CDSR), the Cochrane Library used to include the Database of Abstracts of Reviews of Effects (DARE) and the Health Technology Assessment Database (HTA Database), produced by the Centre for Reviews and Dissemination (CRD) at the University of York in the UK. Both databases provided information on published reviews of the effects of health care (Petticrew et al 1999). Searches of MEDLINE, Embase, CINAHL, APA PsycInfo and PubMed to identify candidate records for these two databases were continued until the end of 2014 and bibliographic records were published on DARE until 31 March 2015. CRD will maintain secure archive versions of DARE until at least the end of March 2024 (https://www.crd.york.ac.uk/CRDWeb). CRD continued to maintain and add records to the HTA database until 31 March 2018. In July 2019, the HTA database records were exported from the CRD platform and imported into the new platform that was developed by the International Network of Agencies for Health Technology Assessment (INAHTA). The rebuild of the new platform was launched in June 2020. The International HTA database (https://database.inahta.org/) provides free access to bibliographic information of approximately 20,000 ongoing and completed/published health technology assessments commissioned or undertaken by HTA organizations internationally (as of May 2023).

Since 1 April 2015 the UK National Institute for Health and Care Research (NIHR) has produced summaries of single NIHR research studies (Alerts) and summaries of several NIHR research studies within a specific theme or health and care topic (Collections and Themed Reviews). Details can be found at https://evidence.nihr.ac.uk/.

KSR Evidence, a subscription database, aims to include all systematic reviews and meta-analyses published since 2015 (https://ksrevidence.com/). KSR Evidence was developed by Kleijnen Systematic Reviews Ltd (KSR) (www.systematic-reviews.com). KSR produces and disseminates systematic reviews, cost-effectiveness analyses and health technology
assessments of research evidence in health care. The database also includes an advanced search option, suitable for information specialists.

CRD provides an international register of prospectively registered systematic reviews in health and social care called PROSPERO (Page et al 2018), which (as of May 2023) contained over 140,000 records (www.crd.york.ac.uk/prospero/). Key features from the review protocol are recorded and maintained as a permanent record. PROSPERO aims to provide a comprehensive listing of systematic reviews registered at inception to help avoid duplication and reduce opportunity for reporting bias by enabling comparison of the completed review with what was planned in the protocol. PROSPERO, therefore, provides access to ongoing reviews as well as completed and/or published reviews.

Epistemonikos is a web-based bibliographic service which provides access to approximately 500,000 systematic reviews (as May 2023) together with other records such as broad syntheses of reviews and structured summaries, and their included primary studies (http://www.epistemonikos.org/en). The aim of Epistemonikos is to provide rapid access to systematic reviews in health. Epistemonikos uses the eligibility criteria specified by the review authors to include primary studies in the database.

The Systematic Review Data Repository (SRDR) and the Systematic Review Data Repository Plus (SRDR+) were both open and searchable archives of systematic reviews and their data (http://srdr.ahrq.gov/ and https://srdrplus.ahrq.gov/) (Saldanha et al 2019). As of December 2021, it was announced that the SRDR resource would be decommissioned on 7 January 2022 and SRDR+ would be the only actively updated resource in future.

Health Systems Evidence, from McMaster, is a repository of evidence syntheses about governance, financial and delivery arrangements within health systems, and about implementation strategies that can support change in health systems. The types of syntheses include evidence briefs for policy, overviews of systematic reviews, systematic reviews, protocols, and registered titles. The audience is policy makers/researchers.

Health Evidence (https://www.healthevidence.org/), also from McMaster, provides access to c. 10,000 quality-rated systematic reviews evaluating the effectiveness and cost-effectiveness of public health interventions, including cost data, relevant to public health (as of July 2023).

Specific evidence-based search services such as Trip (previously known as Turning Research into Practice (TRIP)) (https://www.tripdatabase.com/) can also be used to identify reviews and guidelines (Brassey 2007). For the range of systematic review sources searched by Trip see www.tripdatabase.com/about. Access is offered at two levels: Trip is free of charge and Trip Pro is available on subscription.

SUMSearch 2 (http://sumsearch.org/) simultaneously searches for original studies, systematic reviews, and practice guidelines from multiple sources.
MEDLINE, Embase and other bibliographic databases, such as CINAHL (Wright et al 2015), can also be used to identify review articles and guidelines. For the 2019 release of the Medical Subject Headings (MeSH), Systematic Review was introduced as a Publication Type term. NLM announced: “We added the publication type ‘Systematic Review’ retrospectively to appropriate existing MEDLINE citations. With this re-indexing, you can retrieve all MEDLINE citations for systematic reviews and identify systematic reviews with high precision.”


Embase has a thesaurus (Emtree) term ‘Systematic Review’, which was introduced in 2003. For records prior to 2003, the Emtree terms ‘review’ or ‘evidence-based medicine’ could be used.

Several filters to identify reviews and overviews of systematic reviews in MEDLINE (Boynton et al 1998, Shojania and Bero 2001, Montori et al 2005, Wilczynski and Haynes 2009, Lee et al 2012, Lunny et al 2015, Salvador-Oliván et al 2021) and Embase (White et al 2001, Wilczynski et al 2007, Lee et al 2012) have been developed, tested and published over the years. Until late 2018, the PubMed Systematic Reviews filter under the Clinical Queries link was very broad in its scope and retrieved many references that were not systematic reviews. The strategy was defined by NLM as follows: “This strategy is intended to retrieve citations identified as systematic reviews, meta-analyses, reviews of clinical trials, evidence-based medicine, consensus development conferences, guidelines, and citations to articles from journals specializing in review studies of value to clinicians. This filter can be used in a search as systematic [sb].” An archived version of this search filter is available from the InterTASC Information Specialists’ Sub-Group’s Search Filter Resource at:

https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/home/sr-filter?authuser=0

This search filter was replaced by NLM in late 2018 with a much more precise filter and is defined by NLM as follows: “This strategy is intended to retrieve citations to systematic reviews in PubMed and encompasses: citations assigned the ‘Systematic Review’ publication type during MEDLINE indexing; citations that have not yet completed MEDLINE indexing; and non-MEDLINE citations. This filter can be used in a Pubmed search as systematic [sb].”

Example: exercise hypertension AND systematic [sb]

This filter is also available in PUBMED on the Filters sidebar under ‘Article types’ and on the Clinical Queries screen. The full search filter is available at:


The sensitive Clinical Queries Filters for therapy, diagnosis, prognosis, and aetiology perform well in retrieving not only primary studies but also systematic reviews in PubMed. In a test of the Clinical Queries Filters by the McMaster Health Information Research Unit (HIRU), Wilczynski and colleagues reported that performance could be improved by combining the Clinical Queries Filters with the HIRU systematic review filter using the Boolean operator ‘OR’
As well as filters for study design, some filters are available for special populations, and these might be combined with systematic review filters (Boluyt et al 2008). Research has been conducted to help researchers choose the filter appropriate to their needs (Lee et al 2012, Rathbone et al 2016). Filters and current reviews of filter performance to identify systematic reviews can be found on the InterTASC Information Specialists’ Sub-Group’s Search Filter Resource website (https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/home/systematic-reviews) (Glanville et al 2023). For further information on search filters see Section 3.6 and subsections.

National and regional drug approval and reimbursement agencies may also be useful sources of reviews:

- The Agency for Healthcare Research and Quality (AHRQ) publishes systematic reviews and meta-analyses. Evidence reports, comparative effectiveness reviews, technical briefs, Technology Assessment Program reports, and US Preventive Services Task Force evidence syntheses are available under the Evidence-based Practice Centers (EPC) Program of the Agency for Healthcare Research and Quality. Access to the evidence reports is provided at: https://www.ahrq.gov/research/findings/evidence-based-reports/search.html.

- The Canadian Agency for Drugs and Technologies in Health (CADTH) (https://www.cadth.ca) is an independent, not-for-profit organization responsible for providing healthcare decision-makers with evidence reports to help make informed decisions about the optimal use of drugs, diagnostic tests, and medical, dental, and surgical devices and procedures. CADTH’s Reimbursement Review Reports, Health Technology Assessments, Technology Reviews and Therapeutic Reviews are published in full text on their website and include the full search strategy for the clinical evidence used in that review.

- The National Institute for Health and Care Excellence (NICE) (https://www.nice.org.uk) publishes guidance that includes recommendations on the use of new and existing medicines and other treatments within the National Health Service (NHS) in England and Wales. These reviews can be about medicines, medical devices, diagnostic tests, surgical procedures, or health promotion activities. Each guidance and appraisal document is based on a review of the evidence and reports the searches used.

Clinical guidelines, based on reviews of evidence, may also provide useful information about the search strategies used in their development: see the Appendix for examples of sources of clinical guidelines. Guidelines can also be identified by searching MEDLINE where guidelines should be indexed under the Publication Type term ‘Practice Guideline’, which was introduced in 1991. Embase has a thesaurus term ‘Practice Guideline’, which was introduced in 1994.

The ECRI Guidelines Trust (https://guidelines.ecri.org/) provides access to a free web-based repository of objective, evidence-based clinical practice guideline content. It includes
evidence-based guidance developed by nationally and internationally recognized medical organizations and medical specialty societies. Guidelines are summarized and appraised against the US Institute of Medicine (IOM) Standards for Trustworthiness. The Guidelines Trust provides the following guideline-related content:

- **Guideline Snapshots and Guideline Profiles.**

- **TRUST (Transparency and Rigor Using Standards of Trustworthiness) Scorecards**: ratings of how well guidelines fulfil the IOM Standards for Trustworthiness.

The Agency for Healthcare Research and Quality (AHRQ)’s National Guideline Clearinghouse existed as a public resource for summaries of evidence-based clinical practice guidelines but ceased production in July 2018 with the latest guidelines being accepted for inclusion until March 2018. The resource offered systematic comparisons of selected guidelines that addressed similar topic areas. For further information as to whether this resource will be reintroduced see: [https://www.ahrq.gov/gam/updates/index.html](https://www.ahrq.gov/gam/updates/index.html).

Evidence summaries such as online/electronic textbooks, point-of-care tools and clinical decision support resources are a type of synthesized medical evidence. Examples of these tools include BMJ Best Practice, ClinicalKey, Dynamed/DynaMed Plus and UpToDate in addition to Cochrane’s own point-of-care tool Cochrane Clinical Answers, available within the Cochrane Library. Although they are designed to be used in clinical practice, they offer evidence for diagnosis and treatment of specific conditions and are regularly updated with links to and reference lists to reports of relevant studies which can help in identifying studies, reviews, and overviews. Most evidence summaries for use in clinical practice are available via subscription to commercial vendors.

As noted above, it is mandatory, for authors of Cochrane Reviews of interventions, to check reference lists of included studies and any relevant systematic reviews identified (MECIR C30). Checking reference lists within eligible studies supplements other searching approaches and may reveal new studies, or confirm that the topic has been thoroughly searched ([Greenhalgh and Peacock 2005](https://www.ncbi.nlm.nih.gov/pubmed/15801120), [Horsley et al 2011](https://www.ncbi.nlm.nih.gov/pubmed/21584456)). Examples of situations where checking reference lists might be particularly beneficial are:

- when the review is of a new technology;
- when there have been innovations to an existing technique or surgical approach;
- where the terminology for a condition or intervention has evolved over time; and
- where the intervention is one which crosses subject disciplines, for example, between health and other fields such as education, psychology or social work. Researchers may use different terminology to describe an intervention depending on their field ([O’Mara-Eves et al 2014](https://www.ncbi.nlm.nih.gov/pubmed/24823492)); and
• where a relevant realist review has been identified, as realist review searches are likely to be iterative and rely on a range of supplementary searching techniques (Booth et al 2020, Duddy and Roberts 2022).

It is not possible to give overall guidance as to which of the above sources should be searched in the case of all reviews to identify other reviews, guidelines and reference lists as sources of studies. This will vary from review to review. Review authors should discuss this with their Cochrane Information Specialist, or other medical/healthcare librarian or information specialist.

1.3.5 General web searching (including search engines/Google Scholar, etc.)
Searching the World Wide Web (hereafter, web) involves using resources which are not specifically designed to host and facilitate the identification of studies. This includes general search engines such as Google Search and the websites of organizations that are topically relevant for review topics, such as charities, research funders, manufacturers and medical societies. These resources often have basic search interfaces and host a wide range of content, which poses challenges when conducting systematic searching (Stansfield et al 2016). Despite these challenges web searching has the potential to identify studies that are eligible for inclusion in a review, including ‘unique’ studies that are not identified by other search methods (Eysenbach et al 2001, Ogilvie et al 2005, Stansfield et al 2014, Godin et al 2015, Bramer et al 2017a, Coleman et al 2020). It is good practice to carry out web searching for review topics where studies are published in journals that are not indexed in bibliographic databases or where grey literature is an important source of data (Ogilvie et al 2005, Stansfield et al 2014, Godin et al 2015). Grey literature is literature “which is produced on all levels of government, academics, business and industry in print and electronic formats, but which is not controlled by commercial publishers” (see Section 1.1.6) (Farace and Frantzen 1997, Farace and Frantzen 2005).

It is good practice to base the search terms used for web searching on the search terms used for searching bibliographic databases (Eysenbach et al 2001). A simplified approach, however, might be required due to the basic search interfaces of web resources. For example, web resources are unlikely to support multi-line search strategy development or nested use of Boolean operators, and single-line searching is often limited by a maximum number of alphanumeric characters. As such, it might be necessary to rewrite a search using fewer search terms or to conduct several searches of the same resource using different combinations of search terms (Eysenbach et al 2001, Stansfield et al 2016, Briscoe et al 2020b). In addition to using search terms, web searching involves following links to webpages and websites. This is less structured than searching using pre-specified search terms and the searcher will need to use their discretion to decide when to start and stop searching (Stansfield et al 2016). Wherever possible, a similar approach to searching should be used for different web resources to ensure consistency and searches should be documented in full and reported in the review (see Chapter 4, Section 4.5).
Web resources are unlikely to have a function for exporting results to reference management software, in which case the searcher may decide to screen the results ‘on screen’ while searching. Alternatively, screenshots can be taken and screened at a later time (Stansfield et al 2016). This process can be facilitated by software such as Evernote or OneNote. Because website content can be deleted or edited by the website editor at any time, a permanent record of any relevant studies should be retained.

Web searching should use a combination of search engines and websites to ensure a wide range of sources are identified and searched in depth.

**Search engines**

Due to the scale and diversity of content on the web, searching using a search engine is likely to retrieve an unmanageable number of results (Mahood et al 2014). Results are usually ranked according to relevance as determined by a search engine’s algorithm, so it might be useful to limit the screening process to a pre-specified number of results, e.g. limits ranging from 100 to 500 results have been reported in Cochrane Reviews (Briscoe 2018). Alternatively, an ad hoc decision to stop screening can be made when the search results become less relevant (Stansfield et al 2016). It is good practice to use a more comprehensive approach when screening Google Scholar results, which are limited to 1000, to ensure that all relevant studies, including grey literature, are identified (Haddaway et al 2015). Some search engines allow the user to limit searches to a specified domain name or file type, or to web pages where the search terms appear in the title. These options might improve the precision of a search though they might also reduce its sensitivity. The reported number of results identified by Google Scholar is usually an estimate which varies over time, and the viewable results might be lower than reported (Bramer 2016). Similarly, recent studies show that the viewable number of results in Google Search is typically much lower than the estimated number reported by the search engine (Briscoe and Rogers 2021, Briscoe et al 2023). Search engines often combine search terms using the ‘AND’ Boolean operator by default. Some search engines support additional search operators and features such as ‘OR’, ‘NOT’, wildcards and phrase searching using quotation marks.

There are many freely available search engines, each of which offers a different approach to searching the web. Because each search engine uses a different algorithm to retrieve and rank its results, the results will differ depending on the search engine that is used (Dogpile.com 2007). Thus it might be worth experimenting with or combining use of different search engines to retrieve a wider selection of results. There are freely available meta-search engines which search a combination of search engines, though they are often limited with regard to which search engines can be combined. Some search engines tailor the search results to a user’s search history and location, so the search results might differ between users, thus limiting reproducibility (Cooper et al 2021b). Clearing a web browser’s cache and cookies before searching should, however, reduce the personalization of results (Curkovic and Kosec 2018).
A selection of freely available search engines and meta-search engines is shown in Box 1.a. These are examples of different types of search engine rather than a list of recommended search engines. No specific search engines are recommended for a Cochrane Review.

**Box 1.a Search engines**

**Dogpile** [http://www.dogpile.com/](http://www.dogpile.com/)

Dogpile is a meta-search engine which in a study from 2007 is reported to search Google Search, Yahoo!, Ask and Bing ([Dogpile.com 2007](http://www.dogpile.com/)). A more up to date list of search engines used by Dogpile has not been identified, although the About page on the website states that “Dogpile returns all the best results from leading search engines including Google and Yahoo!”.

**DuckDuckGo** [https://duckduckgo.com/](https://duckduckgo.com/)

DuckDuckGo protects the privacy of its users by not recording their IP addresses and search histories. A potential advantage for systematic review authors is that DuckDuckGo does not use search histories to personalize its search results, which might make it better at ranking less frequently visited but useful pages higher in the results.

**Google Scholar** [https://scholar.google.com/](https://scholar.google.com/)

Google Scholar is a specialized version of Google Search which limits results to scholarly literature, including published studies and grey literature. It cannot be used instead of searching bibliographic databases due to its basic search interface and a block on viewing more than 1000 records per search ([Boeker et al 2013a](https://scholar.google.com/), [Bramer et al 2016a](https://scholar.google.com/)). It can, however, be a useful resource when used alongside bibliographic databases for identifying studies including those reported in grey literature not indexed in bibliographic databases or not retrieved by the bibliographic database search strategies ([Haddaway et al 2015](https://scholar.google.com/), [Bramer et al 2017a](https://scholar.google.com/)). The option to search the full text of studies can contribute to the identification of unique studies when using similar or the same search terms as used in bibliographic databases ([Bramer et al 2017a](https://scholar.google.com/)). References can be exported to reference management software, though the number of references that can be exported at a time is limited to 20 ([Bramer et al 2013](https://scholar.google.com/)). However, Google Scholar can be searched via the freely available Publish or Perish software, which also facilitates bulk exportation of results to reference management software ([Harzing 2007](https://scholar.google.com/)).

**Google Search** [https://www.google.com/](https://www.google.com/)

Google Search is the most widely used search engine worldwide. An advantage of its popularity is that there is an abundance of online material on how to make the most of its advanced search features. The Verbatim feature in the Google Search Tools menu can be used to ensure search results contain the precise search terms used (e.g. will not retrieve
“nursing” if searching for “nurse”) and to switch off the personalization of search results based on websites which the user has previously visited. Personalization can also be deactivated via the settings menu. Google Search can be set to display 100 results per page, which can help to ascertain a more accurate estimate of the total number of results which are viewable for screening than the number estimated by the search engine (Briscoe and Rogers 2021). Studies show that the viewable number of results is typically much lower than the estimated number (Briscoe and Rogers 2021, Briscoe et al 2023).

Not all content on websites is indexed by search engines, so it is important to consider accessing and searching any potentially useful websites which are identified in the search results (Devine and Egger-Sider 2013).

Websites
The selection of websites to search will be determined by the review topic. It is good practice to investigate whether the websites of relevant pharmaceutical companies and medical device manufacturers host trials registers which should be searched for studies. The websites of medicines regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) should be searched for regulatory documentation (see Section 1.2 and subsections). It might also be useful to search the websites of professional societies, national and regional health departments, and health related non-governmental organizations and charities for studies not indexed in bibliographic databases and grey literature (Ogilvie et al 2005, Godin et al 2015, Briscoe et al 2020b).

Searching websites will usually yield a lower number of results than search engines, so it should be possible to screen all the results rather than a pre-specified number.

1.4 Summary points
- Cochrane Review authors should seek advice from a Cochrane Information Specialist, or other medical/healthcare librarian or information specialist, on sources to search.
- Authors of non-Cochrane reviews should seek advice from a medical/healthcare librarian or information specialist, with experience of conducting searches for studies for systematic reviews.
- The key database sources which should be searched are the Cochrane Review Group’s Specialized Register (internally, e.g. via the Cochrane Register of Studies, or externally via CENTRAL), CENTRAL, where such Specialized Registers exist, MEDLINE and Embase (if access to Embase is available to either the review authors or the CRG).
• Appropriate national, regional and subject specific bibliographic databases should be searched according to the topic of the review.

• Relevant grey literature sources such as those containing reports, dissertations/theses and conference abstracts should be searched.

• Searches should be conducted to locate previous reviews on the same topic, to identify additional studies included in (and excluded from) those reviews.

• Reference lists of included studies should be checked to identify additional studies.

• Trials registers and repositories of results where relevant to the topic, should be searched through both ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) portal and other sources as appropriate.

• Regulatory agency sources and clinical study reports should also be considered as sources for study data.

• Citation indexes should be considered as an additional source of relevant studies.

2 Planning the search process

2.1 Cochrane-wide search initiatives and the Cochrane Centralized Search Service (CSS)

In 2015, building on the processes established for the Embase project to identify records from Embase and MEDLINE (see Section 2.1.2), Cochrane began a pilot initiative with the objective of adding to the number of sources to be searched and screened ‘centrally’, known as the Cochrane Centralized Search Service (CSS). The CSS initiative has since been expanded to cover six resources. They are MEDLINE/PubMed (see Section 2.1.1), Embase (see Section 2.1.2), ClinicalTrials.gov (see Section 2.1.3.2), the WHO International Clinical Trials Registry Platform (ICTRP) (see Section 2.1.3.3), KoreaMed (see Section 2.1.3.4) and CINAHL Plus (see Section 2.1.3.5). All sources are searched or queried via an API (Application Programming Interface) each week, with the exception of ClinicalTrials.gov, which is queried daily and CINAHL Plus which is queried monthly. For each source an appropriately sensitive search approach to identifying possible RCTs has been developed and implemented (see Table 2.1.a for an overview, and for further details see the ‘How CENTRAL is created’ file in the Cochrane Library: https://www.cochranelibrary.com/central/central-creation). For both Embase and CINAHL Plus, a methodological search filter has been developed (see Sections 3.6.2 and 3.6.3 respectively).

Each of the CSS sources had ‘backlogs’ to deal with in parallel to setting up prospective routines to identify newly indexed reports of RCTs. The backlogs for all sources (Embase, MEDLINE/PubMed, ClinicalTrials.gov, ICTRP, KoreaMed and CINAHL Plus) have been cleared.
This was achieved by using a combination of machine learning in the form of the RCT Classifier (Thomas et al 2021) and crowdsourcing via the Cochrane Crowd (https://crowd.cochrane.org/). The CSS aims to provide systematic review authors and others with an even baseline of access, via CENTRAL, to the relevant evidence needed to produce systematic reviews and other evidence products. It is unlikely it will ever completely replace the need for some multi-source, bespoke, review-based searches, especially for cross-disciplinary or complex reviews, but it is hoped that it will substantially improve access to RCT evidence and reduce the amount of multi-source searching currently needed. A recent, retrospective analysis showed that 97.5% of RCTs published in 2017 and 2018 that had been included in Cochrane Reviews had been identified by the CSS (Noel-Storr et al 2020).

Information specialists should consider numerous factors when deciding which sources to include in their searches. These include being aware of the time taken for records to appear in CENTRAL from source databases such as MEDLINE and Embase, understanding that across the years different processes and searches have been used to populate CENTRAL, and recognizing that for trials register records not all fields of content available for those records in their source databases are included in CENTRAL. Each of these factors is discussed in more detail in an analysis of the CSS (Noel-Storr et al 2020).

Table 2.1.a is designed to be a quick reference to sources that feed or have recently fed into CENTRAL: Figure 2.a illustrates the contents of CENTRAL.

**Table 2.1.a Sources searched as part of the Cochrane Centralized Search Service (CSS)**

<table>
<thead>
<tr>
<th>Source (provider)</th>
<th>Workflow description (current/most recent)</th>
<th>Harvested from external source</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed* (US National Library of Medicine)</td>
<td>Direct feed of records into CENTRAL based on index terms (MeSH) search: &quot;randomized controlled trial&quot; [Publication Type] OR &quot;controlled clinical trial&quot; [Publication Type]</td>
<td>Weekly API call</td>
</tr>
<tr>
<td>Embase* (Elsevier)</td>
<td>Sensitive search of Embase.com via the Embase.com API using the Cochrane search filter for identifying RCTs in Embase (see Section 3.6.2). • Records with both the Emtree term: Randomized Controlled Trial expl and that receive a high RCT Classifier score are submitted directly to CENTRAL (i.e. both the above criteria must be met). • Records that receive below threshold score by RCT Classifier are discarded. • Remaining records are manually assessed by the Cochrane Crowd.</td>
<td>Weekly API call</td>
</tr>
<tr>
<td>ClinicalTrials.gov (US National Library of Medicine)</td>
<td>All records are downloaded and run through the RCT Classifier. • Records scoring below threshold score are discarded. • Remaining records are manually assessed by the Cochrane Crowd.</td>
<td>Daily API call</td>
</tr>
</tbody>
</table>
| **ICTRP**  
| (World Health Organization) | All records are downloaded.  
|                            | • Records with: (randomised OR randomized) NOT (randomised: no OR randomized: no)) in the study design or study type fields, together with (randomised OR randomized) found in any other field of the record, are directly submitted to CENTRAL, i.e. both the above criteria must be met.  
|                            | • Remaining records are manually assessed by the Cochrane Crowd. | Weekly API call |
| **KoreaMed**  
| (Korean Association of Medical Journal Editors) | All records were downloaded.  
|                            | • Records that received below threshold score by RCT Classifier were discarded.  
|                            | • Remaining records were manually assessed by the Cochrane Crowd. | Monthly API call was on 15th of each month (now discontinued) |
| **CINAHL Plus**  
| (EBSCOhost) | Sensitive search of CINAHL Plus via API using the Cochrane search filter for identifying RCTs in CINAHL (see Section 3.6.3).  
|                            | • Records that receive below threshold score by RCT Classifier are discarded.  
|                            | • Remaining records are manually assessed by the Cochrane Crowd. | Monthly API call on 15th of each month |

*The search of Embase includes MEDLINE/PubMed records.

**As of May 2021, KoreaMed is no longer searched as part of the Cochrane Centralized Search Service.

**Figure 2.a Illustration of the contents of CENTRAL**
2.1.1 What is in the Cochrane Central Register of Controlled Trials (CENTRAL) from MEDLINE?

CENTRAL contains all records from MEDLINE indexed with the Publication Type term ‘Randomized Controlled Trial’ or ‘Controlled Clinical Trial’ except those that are indexed solely as animal studies (not also as human studies). For further details see the ‘How CENTRAL is created’ file in the Cochrane Library:

https://www.cochranelibrary.com/central/central-creation

A substantial proportion of the MEDLINE records coded ‘Randomized Controlled Trial’ or ‘Controlled Clinical Trial’ in the Publication Type field have been coded as a result of early work within Cochrane (Dickersin et al 2002). Handsearch results from Cochrane groups, for journals indexed in MEDLINE, were sent to the US National Library of Medicine (NLM), where the MEDLINE records were re-tagged with the Publication Types ‘Randomized Controlled Trial’ or ‘Controlled Clinical Trial’ as appropriate. In addition, the US Cochrane Center (formerly the New England Cochrane Center, Providence Office and the Baltimore Cochrane Center and now Cochrane US) and the UK Cochrane Centre (now Cochrane UK) conducted a search of MEDLINE from 1966 to 2004 to identify reports of randomized trials, identifiable from the MEDLINE titles and/or abstracts, not already indexed as such, using the first two phases of the original Cochrane Highly Sensitive Search Strategy first published in 1994 (Dickersin et al 1994) and thereafter updated and included in subsequent editions of this Handbook (see Section 3.6.1). The free-text terms used were: clinical trial; (singl$ OR doubl$ OR trebl$ OR tripl$) AND (mask$ OR blind$); placebo$; random$. The $ sign indicates the use of a truncation symbol. The subject heading terms (MeSH) used were (‘exploded’ where possible to include narrower, more specific terms): randomized controlled trials; random allocation; double-blind method; single-blind method; clinical trials; placebos. The following subject heading term (MeSH) was used ‘unexploded’: research design. The Publication Type terms used were: randomized controlled trial; controlled clinical trial; clinical trial.

A test was carried out using the terms in phase three of the 1994 Cochrane Highly Sensitive Search Strategy but the precision of those terms, having already searched on all the terms in phases one and two as listed above, was considered to be too low to warrant using these terms for the above project (Lefebvre and Clarke 2001). It was, however, recognized that some of these terms might be useful when combined with subject terms to identify studies for some specific reviews (Eisinga et al 2007).

The above search was limited to humans. The following years were completed by the US Cochrane Center (1966 to 1984; 1998 to 2004) and by the UK Cochrane Centre (1985 to 1997). The results for these years were forwarded to the NLM and re-tagged in MEDLINE and are thus included in CENTRAL. More recent MEDLINE records, which are now included, under licence, in Embase, are being searched as part of the Cochrane Centralized Search Service (see Section 2.1.2).
CENTRAL includes from MEDLINE not only reports of trials that meet the more restrictive Cochrane definition for a quasi-randomized trial (indexed in MEDLINE as ‘Controlled Clinical Trial’) (Box 2.a) but also trial reports that meet the less restrictive NLM definition (Box 2.b) which includes historical comparisons. There is currently no method of distinguishing, either in CENTRAL or in MEDLINE, which of these records meet the more restrictive Cochrane definition, as they are all indexed with the Publication Type term ‘Controlled Clinical Trial’.

**Box 2.a Cochrane definitions and criteria for randomized controlled trials (RCTs) and quasi-randomized trials**

Records identified for inclusion in CENTRAL should meet the eligibility criteria devised and agreed in November 1992, which were first published, in 1994, in the first version of this Handbook (Oxman et al 1994). According to these eligibility criteria:

A trial is eligible if, on the basis of the best available information (usually from one or more published reports), it is judged that:

- the individuals (or other units) followed in the trial were definitely or possibly assigned prospectively to one of two (or more) alternative forms of health care using:
  - random allocation; or
  - some quasi-random method of allocation (such as alternation, date of birth, or case record number).

Trials eligible for inclusion are classified according to the reader’s degree of certainty that random allocation was used to form the comparison groups in the trial. If the author(s) state explicitly (usually by some variant of the term ‘random’ to describe the allocation procedure used) that the groups compared in the trial were established by random allocation, then the trial is classified as a RCT (randomized controlled trial). If the author(s) do not state explicitly that the trial was randomized, but randomization cannot be ruled out, the report is classified as a CCT (controlled clinical trial). The classification CCT is also applied to quasi-randomized studies, where the method of allocation is known but is not considered strictly random, and also trials that are possibly quasi-randomized. Examples of quasi-random methods of assignment include alternation, date of birth, and medical record number.

The classification as RCT or CCT is based solely on what the author has written, not on the reader’s interpretation; thus, it is not meant to reflect an assessment of the true nature or quality of the allocation procedure. For example, although ‘double-blind’ trials are nearly always randomized, many trial reports fail to mention random allocation explicitly and should therefore be classified as CCT.
Relevant reports are reports published in any year, of studies comparing at least two forms of health care (healthcare treatment, healthcare education, diagnostic tests or techniques, a preventive intervention, etc.) where the study is on either living humans or parts of their body or human parts that will be replaced in living humans (e.g. donor kidneys). Studies on cadavers, extracted teeth, cell lines, etc. are not relevant. **Searchers should identify all controlled trials meeting these criteria regardless of relevance to the entity with which they are affiliated.**

The highest possible proportion of all reports of controlled trials of health care should be included in CENTRAL. Thus, those searching the literature to identify trials should give reports the benefit of any doubts. Review authors will decide whether to include a particular report in a review.

In 2013, a Cochrane working group was formed to review the record type eligibility for CENTRAL and to ensure consistency of practice and guidance for the Embase project and handsearcher training. This group focused on types of report rather than types of study. The group determined that reports of protocols for randomized or quasi-randomized trials, along with letters, replies, errata, and retractions relating to RCTs or quasi-RCTs are all to be included in CENTRAL.

**Box 2.b US National Library of Medicine 2023 definitions (Scope Notes) for the Publication Type terms ‘Randomized Controlled Trial’ and ‘Controlled Clinical Trial’**

**Randomized Controlled Trial**
A work that reports on a clinical trial that involves at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.

**Controlled Clinical Trial**
A work that reports on a clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterized as a RANDOMIZED CONTROLLED TRIAL.
MEDLINE records are also currently being added into CENTRAL from Embase. Since 2010, Elsevier has included MEDLINE records in Embase under licence with the US National Library of Medicine (see further details in Section 2.2.2 on specific issues when searching MEDLINE and Embase).

2.1.2 What is in the Cochrane Central Register of Controlled Trials (CENTRAL) from Embase?

A retrospective search conducted by the UK Cochrane Centre (now Cochrane UK) for reports of trials in Embase was undertaken for the years 1974 to 2010. For the years 1974 to 1979, the free-text terms: random$; factorial$; crossover$; cross-over$; and placebo$ were used. For the years 1980 to 2008, the following free-text terms: random$; factorial$; crossover$; cross-over$; cross over$; placebo$; double$ adj blind$; single$ adj blind$; assign$; allocat$; volunteer$; and the following index terms, known as Emtree terms: crossover-procedure; double-blind procedure; randomized controlled trial; single-blind procedure were used. For 2009, the following free-text terms: random$; crossover$; cross-over$; cross over$; placebo$; double$ adj blind$; single$ adj blind$; assign$; allocat$; and the following index terms, known as Emtree terms: crossover-procedure; double-blind procedure; randomized controlled trial; single-blind procedure were used. In addition, the following terms were searched limited to the title only: trial; comparison. For 2010, the following free-text terms were searched limited to the title, abstract and original title fields only: crossover$, cross over$, placebo$, double$ adj blind$, single$ adj blind$, allocat$, and the following index terms were searched: crossover-procedure; double-blind procedure; single-blind procedure and randomized controlled trial. (Note: cross over$ includes cross-over$ in Ovid syntax).

The searches across all years of this project (1974 to 2010) yielded a total of approximately 100,000 reports of trials not indexed, at the time of the search, as randomized controlled trial or controlled clinical trial in MEDLINE. All of these reports are now published in CENTRAL (Lefebvre et al 2008). The final submission of reports under this project, of trials identified in journal article records added to Embase in 2010, was published in CENTRAL in February 2012. This project then formally ended, with a newly funded project starting in 2013.

In March 2013, Cochrane launched a further Embase project to provide ongoing screening of records from Embase to identify additional reports of trials. This project was co-ordinated by Metaxis Ltd., the Cochrane Dementia and Cognitive Improvement Group and York Health Economics Consortium. Initially, a search covering January 2011 to December 2013, inclusive, was run, from which approximately 30,000 unique Embase records were identified and published in CENTRAL, January 2014 (Issue 1). All these records were identified from a search in Embase (via Ovid) using the Emtree headings Randomized Controlled Trial (RCT) or Controlled Clinical Trial (CCT). It is estimated that this search, using only these two headings, identified two-thirds of records eligible for inclusion in CENTRAL from the 2011 to 2013 period.
The remaining records were identified using the search strategy developed by the UK Cochrane Centre (now Cochrane UK), described above, with records indexed as either RCT or CCT removed, as those records had already been identified and added to CENTRAL. A small team of expert screeners screened the results retrieved and identified a further 20,000 records eligible for CENTRAL.

In parallel to the work described above, a new search filter to identify potential reports of randomized trials in Embase was developed in 2013 and initiated in January 2014 (Glanville et al 2019b). It was developed following an examination of 1000 relevant reports (reference standard) of randomized trials, and was tested on a second set of 1000 records. The filter was tiered. The first tier identified records with the most relevant Embtree headings RANDOMIZED CONTROLLED TRIAL or CONTROLLED CLINICAL STUDY. The second tier comprised search terms likely to find records from the reference standard which did not contain those two Embtree headings. The revised filter was used from January 2015. It was initially run as two searches with records containing Embtree terms RANDOMIZED CONTROLLED TRIAL or CONTROLLED CLINICAL STUDY being directly fed into CENTRAL. The remaining records retrieved by the new filter were sent for manual screening via the Cochrane Crowd. Minor revisions to the filter were made in 2017 and 2021. These revisions were aimed at reducing the number of non-RCTs being fed directly into CENTRAL and reducing the number of animal RCTs identified. For details of the current process and filter used, see https://www.cochranelibrary.com/central/central-creation.

Currently, records are screened using a crowdsourcing model, accessible from the Cochrane Crowd platform (https://crowd.cochrane.org/). Here, Cochrane contributors and members of the general public can contribute to screening records after completing a brief training exercise. As of February 2023 over 2 million Embase records had been collectively screened, and over 150,000 additional reports of trials had been identified and added to CENTRAL.

In 2009, Elsevier began adding conference records to Embase, and to date (February 2023) has added about 4.5 million conference abstracts from about 12,000 conferences (https://beta.elsevier.com/products/embase/content?trial=true). The addition of conference abstracts in Embase created a sizable backlog of records for the Cochrane Centralized Search Service. The Embase screening project searched and downloaded all records (not just conference abstracts) added to Embase between 2010 and 2013 inclusive. The search strategy used for the conference ‘backlog’ was the most recent version in use by the UK Cochrane Centre. This was so that screening of this backlog could get underway quickly whilst the new search filter was being developed. All reports of RCTs identified from the screening of these records had been published in CENTRAL by the end of 2014.

Introducing machine learning into the workflow

In January 2016 the machine learning RCT Classifier was used for the first time on records identified from Embase via the monthly sensitive search described above. Records that received a likelihood score below a pre-specified cut-off-point were deemed to be not RCTs
and no further action was taken on them. Those records that scored on or above the cut-off-point were then sent to the Cochrane Crowd for manual assessment. This remained the workflow for Embase records from the start of 2016 until February 2023. From February 2023 onwards, records with both the Emtree term: Randomized Controlled Trial exp and that receive a high RCT Classifier score are submitted directly to CENTRAL (i.e. both the above criteria must be met); records that have been indexed with the Emtree term: Randomized Controlled Trial exp but receive a low RCT Classifier score are sent to Cochrane Crowd for manual screening. Work to evaluate the potential and the performance of the RCT Classifier can be found in (Wallace et al 2017) (Marshall et al 2018, Thomas et al 2021). In terms of the application of the RCT classifier to the central feed of Embase records, approximately 50% of records score below the currently used cut-off-point representing a significant reduction in manual screening required by the Cochrane Crowd. (See Chapter 4, Section 4.6.6.2 for further information about using machine learning to classify reports of RCTs.)

2.1.3 What is in the Cochrane Central Register of Controlled Trials (CENTRAL) from other non-Cochrane sources and handsearching?

2.1.3.1 Introduction

Many CRGs and Fields have undertaken searching of the specialist healthcare literature (both journals and databases) in their areas of interest. More than 3000 journals have been, or are being, handsearched. Identified trial reports that are not relevant to a CRG’s scope and thus are not appropriate for their Specialized Register (see Section 2.1.4) are published in CENTRAL as handsearch results. Handsearch records can be identified in CENTRAL as they are assigned the tag HS-HANDSRCH in addition to a source code indicating the Centre, Field or Review Group that submitted the record (see https://www.cochranelibrary.com/central/central-creation).

The Australasian Cochrane Centre (now Cochrane Australia) co-ordinated a search of the National Library of Australia’s Australasian Medical Index from 1966 (McDonald 2002). This search was updated to include records added up to December 2009, when the database ceased to be updated. All records identified have been added to CENTRAL.

The Chinese Cochrane Center (now Cochrane China), with support from the Australasian Cochrane Centre (now Cochrane Australia), the UK Cochrane Centre (now Cochrane UK) and Cochrane centrally co-ordinated a search of the Chinese Biomedical Literature Database (CBM) from 1978 to 2008 and identified approximately 30,000 reports of trials. These records have not been added to CENTRAL.

2.1.3.2 Records from ClinicalTrials.gov

From August 2017, eligible ClinicalTrials.gov (CT.gov) (https://clinicaltrials.gov/) records are being identified and systematically added to CENTRAL through Cochrane’s Centralized Search Service.
Process description

All CT.gov records go through Cochrane’s RCT Classifier developed specifically for CT.gov records. The CT.gov RCT Classifier provides likelihood scores for each record being either a randomized or quasi-randomized trial report. Records with an 80% or greater likelihood score are submitted directly to CENTRAL. Records with a 10% or less likelihood score are rejected without any further action. Records with a likelihood score between 11 and 79% inclusive are sent to the Cochrane Crowd to be manually screened. Performance evaluations, conducted internally by the Centralized Search Service Team, show over 99% accuracy at the thresholds described above.

Field mappings

The CT.gov records contain many fields, but not all fields are included in CENTRAL. The fields that are displayed in CENTRAL are the Public and Scientific titles, the URL to the register record, the brief summary of the trial, MeSH, and the “date first received” (i.e. the date the record was first processed in ClinicalTrials.gov). The following data fields from ClinicalTrials.gov have not been republished in CENTRAL: Recruitment status, Study results, Condition, Intervention, Sponsor, Gender, Age, Phase, Enrolment, Funded by, Study type, Study design, Other IDs, Start date, Completion date, Last updated, Last verified, Acronym, Primary completion date, Outcome measures.

2.1.3.3 Records from the WHO’s International Clinical Trials Registry Platform (ICTRP)

The World Health Organization’s International Clinical Trials Registry Platform (ICTRP) (https://trialsearch.who.int/) is a meta-register containing trials data from 20 national and international registers. Since July 2018, eligible trial register records from ICTRP are being identified and systematically added to CENTRAL through Cochrane’s Centralized Search Service (CSS). As with ClinicalTrials.gov, only ICTRP records for RCTs or quasi-RCTs are being added to CENTRAL; other study designs are not included.

Process description

The prospective workflow for identifying reports of RCTs and quasi-RCTs from ICTRP uses both a ‘direct feed’ search (for records that are extremely likely to be describing a randomized trial) and a process of manual screening via the Cochrane Crowd. The search query used for the direct feed is: \{\text{(randomised OR randomized) NOT (randomised: no OR randomized: no)}\} in the study design or study type fields, together with \text{(randomised OR randomized)} in any other field of the record, i.e. both the above criteria must be met. All other newly added ICTRP records are sent to Cochrane Crowd for screening. Note that ‘no’ in the ICTRP entry above refers to the picklist value selected by those registering their trial in ICTRP to indicate that the trial is not a randomized controlled trial. Records where the picklist value was ‘no’ in answer to this question about study design were excluded from the set of records directly fed into CENTRAL. Instead they were manually screened.
Field mappings

Not all fields for ICTRP records are included in CENTRAL. The fields that are included are Public and Scientific titles, the URL for the register record on ICTRP, the Key inclusion and exclusion criteria (which are mapped to the abstract field), the date of registration (mapped to the year field), and the Study ID and the Source register.

2.1.3.4 Records from KoreaMed

KoreaMed (https://www.koreamed.org) is a database provided by the Korean Association of Medical Journal Editors that contains citations to articles published in Korean medical, dental, nursing and nutrition-related journals. This database was routinely searched and records systematically added to CENTRAL through Cochrane’s Centralized Search Service (CSS) until 1 May 2021.

Process description

Inception to December 2013

A project led by Cochrane Australia, in partnership with KoreaMed, sought to identify all unique reports of randomized trials across all dates within the database. As part of this work a search strategy was developed and run in KoreaMed. The search strategy was:


That work identified approximately 3000 unique reports of randomized trials, which were published in CENTRAL in April 2015.

January 2014 to July 2017

Between January 2014 and up to and including June 2017, all records that were added to KoreaMed within that time frame were manually screened by the Centralized Search Service team, with approximately 1000 records submitted to CENTRAL during this time.

August 2017 onwards

From August 2017, a new process was implemented. All KoreaMed records went through the Cochrane RCT Classifier and the Cochrane Crowd (https://crowd.cochrane.org/). Records that received a likelihood score (as described above for ClinicalTrials.gov records) of 10% or less were automatically rejected; records that received a score of 11% or above were sent to Cochrane Crowd for manual screening.
2.1.3.5 Records from CINAHL Plus

In November 2018 a memorandum of understanding was signed between Cochrane, Wiley and CINAHL Plus provider EBSCO (https://www.ebsco.com/products/research-databases/cinahl-database) to enable publication of unique CINAHL Plus records in CENTRAL.

Process description

Since May 2020, CINAHL Plus references to RCTs and quasi-RCTs have been identified and added to CENTRAL through Cochrane’s Centralized Search Service. The CINAHL Plus RCT filter search was developed by Julie Glanville, York Health Economics Consortium, as shown below:

(MH randomized controlled trials OR MH double-blind studies OR MH single-blind studies OR MH random assignment OR MH pretest-posttest design OR MH cluster sample OR TI (randomised OR randomized) OR AB (random*) OR TI (trial) OR (MH (sample size) AND AB (assigned OR allocated OR control)) OR MH (placebos) OR PT (randomized controlled trial) OR AB (CONTROL W5 GROUP) OR MH (CROSSOVER DESIGN) OR MH (COMPARATIVE STUDIES) OR AB (CLUSTER W3 RCT)) NOT ((MH ANIMALS+ NOT MH HUMAN) OR (MH (ANIMAL STUDIES) NOT MH (HUMAN)))

The CINAHL Plus RCT filter search was validated and published in February 2019 by Glanville et al (Glanville et al 2019a). The filter was adapted as an API direct feed by Metaxis in October 2019 and results were screened for inclusion in CENTRAL by Cochrane’s RCT Classifier and by the Cochrane Crowd. Records that receive a score below the threshold for the RCT Classifier are discarded; the remaining records are sent to Cochrane Crowd for manual assessment.

2.1.4 What is in the Cochrane Central Register of Controlled Trials (CENTRAL) from Specialized Registers of Cochrane Review Groups and Fields?

Many CRGs and some Fields develop and maintain a Specialized Register, which aims to contain all relevant studies in their area of interest. These individual registers, together with other relevant records from other sources, are stored together as a single Cochrane Register of Studies (CRS), public records of which can be accessed by any Cochrane member logged into their Cochrane Account via the Cochrane Register of Studies Online (CRSO) (https://crso.cochrane.org/). (Note: this web address can only be accessed when logged in as above.) These public records are also published in CENTRAL in the Cochrane Library. The purpose of the Specialized Register is to assemble a repository of reports of trials relating to the scope of a CRG or Field, to provide a reliable pool of trials for review authors that is easily retrievable, and to share this content with users of the Cochrane Library, via CENTRAL (Cochrane Information Specialist Support Team 2021b). Many of these Specialized Registers are reference-based registers, where each record represents a report of a clinical trial. Where there are multiple reports of a clinical trial, as is typical, there will be multiple records for that trial. Such registers are very similar to a bibliographic database (Wieland et al 2013). Some CRGs/Fields manage a study-based register, where the reports related to each clinical trial or study have been linked together, and identified by a study name (Shokraneh and Adams 2017). In this case, there should only be one record for each clinical trial or study, with all the reports
of that clinical trial or study linked to the study record. In some of these groups, the Cochrane Information Specialist also extracts metadata about studies such as the study participants, the research question, interventions, outcomes, and study designs (Shokraneh and Adams 2017).

Specialized Registers primarily contain reports of randomized and quasi-randomized trials, however, some CRGs add other types of reports to their register, such as controlled before-and-after studies and interrupted time series (Cochrane Information Specialist Support Team 2021b). Whether or not these are added to the Specialized Register will depend on the scope of the CRG. These publication types can be published in CENTRAL. CRGs can also add other reports to their register that may be useful to review authors (such as systematic reviews or background articles), but these would not be published in CENTRAL (Falzon and Trudeau 2007).

It is mandatory, for all Cochrane Reviews of interventions, to search the Cochrane Review Group’s (CRG’s) Specialized Register (internally, e.g. via the Cochrane Register of Studies, or externally via CENTRAL (MECIR C24)), where such a Specialized Register exists. The Specialized Register serves to ensure that individual review authors within the CRG have easy and reliable access to trials relevant to their review topic, normally through a Cochrane Information Specialist. Records in a CRG’s Specialized Register will often contain additional metadata and other information not included in CENTRAL, so the Cochrane Information Specialist may be able to identify additional records in their Specialized Register which could not be identified by searching the Register via CENTRAL. Conversely, the search functionality of the bibliographic or other software used to manage Specialized Registers is usually less sophisticated than the search functionality available in the Cochrane Library (for example, the ability to ‘explode’ MeSH terms to include narrower, more specific terms), so a search of CENTRAL might retrieve records from the Specialized Register that may not be easily retrievable from within the Specialized Register itself. It is therefore recommended that both CENTRAL and the Specialized Register itself are searched separately to maximize retrieval.

CRGs use the methods described in Chapter 4 and this online Technical Supplement to identify trials for their Specialized Registers. Many CRGs also have systems in place to ensure that any additional eligible reports identified by authors for their review(s) are contributed to the CRG’s Specialized Register. By sharing these registers in CENTRAL, records identified by one CRG become accessible to all others. Some Fields also develop subject-specific Specialized Registers for inclusion in CENTRAL as described above. To identify records in CENTRAL from a specific Centre, CRG or Field, it is possible to search on a Specialized Register or Handsearch code (such as SR-STROKE for records from the Cochrane Stroke Group). A list of all the Specialized Register and Handsearch codes can be found in an Appendix in the ‘How CENTRAL is created’ file in the Cochrane Library entitled: CENTRAL codes for records submitted from Cochrane Review Groups, Geographic Groups, Fields, and Networks: https://www.cochranelibrary.com/central/central-creation.
2.2 Searching CENTRAL, MEDLINE, Embase, ClinicalTrials.gov and the ITRP: specific issues

For discussion of some of the specific issues around searching for medical devices, please refer to this recent brief method note (Cooper et al 2022).

2.2.1 Searching the Cochrane Central Register of Controlled Trials (CENTRAL): specific issues

CENTRAL, accessible via the Cochrane Library or from the Cochrane Register of Studies Online (CRSO), comprises records from a wide range of sources (see Section 2.1 and subsections). The consistency and formatting of these records therefore varies. In 2013, Cochrane ran a CENTRAL “clean-up” project. The aims of this project were to clean and harmonize as many fields as possible in existing records, and to formalize standards for Cochrane Information Specialists and/or automatically apply solutions in the CRS to help prevent inconsistencies in the future.

Additionally in 2013, Cochrane formed a working group called HarmoniSR (HarmoniSR Working Group 2015). The scope of this group was initially focused on the formatting of ClinicalTrials.gov records as citations for consistent use within Cochrane Reviews and publication within CENTRAL. The scope of the group, however, expanded during 2014 onwards to include the formatting of all main record types. Despite these ongoing efforts, legitimate differences between records remain, for example, records sourced from MEDLINE will contain Medical Subject Headings (MeSH), whilst ‘native Embase’ records identified from Embase will most likely contain Emtree terms.

Not all records in CENTRAL have an abstract. Optimal searches will, therefore, be those that contain both Medical Subject Headings (MeSH) and free-text terms. The 800,000 records sourced from PubMed are also best retrieved by a combination of MeSH (as the Cochrane Library has a MeSH search interface) together with free-text terms. The other records, including the 700,000 records sourced from Embase, are best retrieved using free-text searches across all fields, as there is no Emtree search interface built into the Cochrane Library. Many of the records that are not sourced from PubMed or Embase (about 800,000 in CENTRAL in July 2023) have neither an abstract or a traditional bibliographic abstract in the case of trial registry records) nor any indexing terms. To retrieve these records, it may be necessary to carry out a very broad search consisting of a wide range of free-text terms, which may be considered too broad to run across all the records in CENTRAL. To isolate the records in CENTRAL to those that are not sourced from PubMed or Embase, it is necessary to use the syntax below in ‘Search manager’: * NOT (Embase:an OR PubMed:an) (i.e. asterisk space NOT etc).

It is highly desirable that authors of Cochrane Reviews of interventions use specially designed and tested search filters where appropriate but filters should not be used in pre-filtered databases e.g. do not use a randomized trial filter in CENTRAL (MECIR C34) or attempt to apply a limit to ‘human’ studies. All records in CENTRAL should be reports of trials in humans even though this may not be apparent from the record itself, especially for those records with no abstract.
As of May 2023, CENTRAL contains approximately 470,000 trial register records. These records have been identified as RCTs through Cochrane’s Centralized Search Service and cover trial register records from ClinicalTrials.gov and the registers included in the meta-register ICTRP. An evaluation is underway to assess the comprehensiveness of CENTRAL for trial register records. A 2020 analysis concluded that CENTRAL was not yet comprehensive enough in terms of trial register report coverage (Banno et al 2020). The Cochrane Evidence Pipeline Team has worked to improve the centralized feeds and an updated analysis is due in 2024.

2.2.2 Searching MEDLINE and Embase: specific issues
Irrespective of the fact that both MEDLINE and Embase have been searched systematically for reports of trials for certain years and that these reports of trials have been included in CENTRAL, as described in Sections 2.1.1 and 2.1.2, supplementary searches of both MEDLINE and Embase are recommended (as detailed below). Any such searches, however, should be undertaken in the knowledge of what searching has already been conducted to avoid duplication of effort.

Searching MEDLINE
There can be a delay of up to one month between records being indexed as trials in MEDLINE and appearing indexed as trials in CENTRAL. This is due to the Cochrane Library monthly updating/publication cycle for CENTRAL. As a cautious approach, therefore, the most recent two months of MEDLINE should be searched, at least for records indexed as either ‘Randomized Controlled Trial’ or ‘Controlled Clinical Trial’ in the Publication Type, to identify those records recently indexed as RCTs or CCTs in MEDLINE. For further details on the search process for MEDLINE see: https://www.cochranelibrary.com/central/central-creation.

Additionally, the most recent year to be searched under the project to identify reports of trials in MEDLINE and send them back to the US National Library of Medicine for re-tagging was 2004, so records added to MEDLINE between 2005 and 2010 inclusive should be searched using one of the Cochrane Highly Sensitive Search Strategies for identifying randomized trials in MEDLINE (see Section 3.6.1). A project is planned to identify potentially missing reports from CENTRAL from this period (2005 to 2010). The project will be designed and set up as a discrete Cochrane Crowd task. (Records added to MEDLINE from 2011 onwards will have been searched as part of the Embase project described in Section 2.1.2).

Finally, for extra sensitivity, or where the use of a randomized trial filter is not appropriate, review authors should search MEDLINE for all years using appropriate free-text and thesaurus terms relevant to their review topic without any trial filter.

The MEDLINE re-tagging project described in Section 2.1.1 assessed whether the records identified were reports of trials on the basis of the title and abstract only. Any supplementary search of MEDLINE that is followed up by accessing the full text of the articles will identify additional reports of trials, most likely through the methods sections, that were not identified through the titles or abstracts alone. It is not expected, however, that accessing the full text of
all articles will be routinely undertaken. For guidance on running separate search strategies in
the MEDLINE-indexed versions of MEDLINE and the versions of MEDLINE containing ‘in-process’
and other non-indexed records please refer to Section 3.6.1.

Any reports of trials identified by the review author should be submitted to the Cochrane
Information Specialist who can ensure that they are added to CENTRAL. Any errors, in respect
of records indexed as trials in MEDLINE that on the basis of the full article are definitely not
reports of trials according to the definitions used by the US National Library of Medicine (NLM)
(see Box 2.b), should also be reported to the Cochrane Information Specialist, so they can be
referred to the NLM and corrected.

For general information about searching, which is relevant to searching MEDLINE, see Section
3 and subsections.

**Searching Embase**

Since 2011, the Emtree term ‘randomized controlled trial’ has been used by Elsevier only to
index records that are reports of trials, not also for records that are about trials (as was
previously the case). This change in indexing practice has made the use of the term much more
precise in identifying possibly relevant studies in Embase. Users can use ‘randomized
controlled trial (topic)’ [exact Ovid syntax: "randomized controlled trial (topic)"] to help find
records about RCTs. As well as the new Cochrane Embase filter (see Section 3.6.2) other search
filters for searching for trials in Embase are available on the InterTASC Information Specialists’
Sub-Group website (https://sites.google.com/a/york.ac.uk/issg-search-filters-
resource/home/rcts).

Additionally, for extra sensitivity, or where the use of a randomized trial ‘filter’ is not
appropriate, review authors should search Embase for all years using appropriate free-text and
thesaurus terms relevant to their review topic without any trial filter, as described under similar
circumstances for MEDLINE above.

It should be remembered that Cochrane’s Centralized Search Service processes are based on
assessing the vast majority of records identified as potential reports of trials on the basis of
the title and abstract only. A small subset of records that have been classified Unsure by ‘Resolver’
level screeners in the Cochrane Crowd do go to full-text assessment. To date this has
accounted for less than 1% of all records screened. Therefore, any supplementary search of
Embase that is followed up by accessing the full text of the articles is likely to identify additional
reports of trials, probably through the methods sections, that were not identified through the
titles or abstracts alone.

There is a delay of some weeks between records being indexed in Embase and appearing in
CENTRAL. The most recent months of Embase should, therefore, be searched. For more details
on the Embase records workflow, go to: https://www.cochranelibrary.com/central/central-
creation. Also see Table 2.1.a.
In 2011, Elsevier began to include all MEDLINE content in Embase. Before then, there had always been a sizable but not complete overlap in content between the two sources. Currently (as of February 2023), Embase provides access to approximately 11000 currently published journals. This includes approximately 3,000 journals that are not covered by MEDLINE (https://beta.elsevier.com/products/embase/content?trial=true). A search of MEDLINE, either through PubMed or through another third-party interface that includes PubMed records, is, however, still necessary. There are records in MEDLINE which have the status: PubMed-not-MEDLINE. Records with this status are “Citations that will not receive MEDLINE indexing because they are for articles in non-MEDLINE journals, or they are for articles in MEDLINE journals but the articles are out of scope, or they are from issues published prior to the date the journal was selected for indexing, or citations to articles from journals that deposit their full text articles in PMC but have not yet been recommended for indexing in MEDLINE” (https://pubmed.ncbi.nlm.nih.gov/help/#citation-status-subsets). In addition, a study found that records from MEDLINE were not always retrieved when searched through Embase due to MeSH not being available in Embase (Bramer et al 2017a). Although it is, therefore, technically possible to search across all MEDLINE records in Embase (note, not all PubMed records), it is recommended that both databases should be searched separately.

As noted above, in 2009 Elsevier began indexing conference abstracts for Embase and about 4.5 million conference abstracts from about 12,000 conferences (as of February 2023) are now indexed in Embase. Elsevier provides a list of conferences they index for Embase, as mentioned above: https://beta.elsevier.com/products/embase/content?trial=true. Conference abstracts can be a rich source of RCT evidence. Within Embase, these records have been indexed using automated indexing procedures, and in most cases the index terms applied automatically are about subject topics or content rather than study type. In addition, many conference abstracts have been retrospectively added to Embase, some of which have been assigned an entry date prior to the publication date of the conference abstract itself. The Embase project has made, and continues to make, efforts to identify conference records added retrospectively. It should be noted, however, that the project may not yet have identified all relevant conference publications.

2.2.3 Searching ClinicalTrials.gov and WHO ICTRP: special issues

As noted above, records from trials registers are included in CENTRAL. They are added as part of Cochrane’s Centralized Search Service (see Section 2.1). Two trials register sources are searched centrally for CENTRAL: ClinicalTrials.gov and the meta-register WHO ICTRP. To identify trials register records in CENTRAL, users can search for: Trial registry record: pt.

Records that are sourced for CENTRAL from trials registers undergo formatting to enable their publication in CENTRAL. This involves field mapping to ensure that the most useful information in the source register record is available for searching in the CENTRAL record, however, not all metadata from the source records is available in CENTRAL. The list of fields available in CENTRAL for ClinicalTrials.gov and ICTRP records is displayed along with their CENTRAL field
mapping in the How CENTRAL is created file at: https://www.cochranelibrary.com/central/central-creation. In particular, records sourced for CENTRAL from ClinicalTrials.gov do not contain the trial results in CENTRAL, even if the original record within ClinicalTrials.gov contains posted results. Nor is there any indication in the CENTRAL record as to whether the original record within ClinicalTrials.gov contains posted results and/or associated publications. Similar issues apply to records sourced from the ICTRP. Direct searches at source of ClinicalTrials.gov and the ICTRP will, therefore, identify not only records not identifiable in CENTRAL but will also provide useful information about any posted results and/or related publications.

MeSH is available for ClinicalTrials.gov records. MeSH terms, however, have been added at source (i.e. by the creators of the source record, not by the US NLM) and are often minimal. Searches should therefore not be based on MeSH alone but on a combination of both free text and MeSH terms.

### 2.3 Summary points

- Cochrane Review authors should seek advice from a Cochrane Information Specialist, or other medical/healthcare librarian or information specialist, on the search process.

- Authors of non-Cochrane reviews should seek advice from a medical/healthcare librarian or information specialist, with experience of conducting searches for studies for systematic reviews.

- The key databases to be searched are the Cochrane Review Group’s Specialized Register (internally, e.g. via the Cochrane Register of Studies, or externally via CENTRAL), where such Specialized Registers exist, CENTRAL, MEDLINE and Embase (if access is available to either the review author or the CRG).

- Approximately 1,000,000 of the 2,000,000 records in CENTRAL are from MEDLINE or Embase, so care should be taken when searching MEDLINE and Embase to avoid unnecessary duplication of effort.

- Supplementary searches of Embase and MEDLINE should be carried out as outlined in Section 2.2.2.

- Supplementary searches of ClinicalTrials.gov and WHO ICTRP should be carried out as outlined in Section 2.2.3.

- Additional studies can be identified in MEDLINE and Embase by searching across the years already searched for CENTRAL, by obtaining the full article and by reading, in particular, the methods section, however, it is not expected that accessing the full text of all articles will be routinely undertaken. The same issues apply to other sources searched for CENTRAL.
3 Designing search strategies: further considerations

This section should be read in conjunction with Chapter 4, Section 4.4. For discussion of some of the specific issues around searching for medical devices, please refer to this recent brief method note (Cooper et al 2022).

3.1 Service providers and search interfaces

Access to MEDLINE, Embase and other general and subject-specific databases is offered by several commercial service providers, via a range of search interfaces. In addition, the US National Library of Medicine, provider of MEDLINE, and Elsevier, provider of Embase, offer access to their own versions of their databases: MEDLINE through PubMed, which is available free of charge on the Internet, and Embase through Elsevier directly, which is known as Embase.com and is available on subscription only. Each interface offers certain functionalities and unique features (Bethel and Rogers 2014) but more importantly the search syntax varies across the interfaces. For example, to search for the Publication Type term ‘Randomized Controlled Trial’ in MEDLINE via different search interfaces it is necessary to enter the term as:

- PT Randomized Controlled Trial (in MEDLINE on EBSCOhost);
- Randomized Controlled Trial.pt. (in MEDLINE on Ovid);
- DTYPE (Randomized Controlled Trial) (in MEDLINE on ProQuest); and
- Randomized Controlled Trial[pt] (in PubMed).

Although the interfaces may offer access to the same database, running the same strategy in the same database but through different interfaces may result in different search results (Schoonbaert 1996, Younger and Boddy 2009, Boeker et al 2013b, Craven et al 2014, Burns et al 2019, Burns et al 2021). Refer to the search help sections of the guidance provided by the relevant service providers and for the specific databases for further information on specific syntax etc.

In addition to accessing bibliographic records, many service providers offer links to full-text versions of articles on other publishers’ websites, such as the PubMed ‘full text links’ feature. Developments in the publishing industry also allow users to add the DOI number, where available, after the text ‘https://doi.org/’ to retrieve the permanent location of an article on the Internet.

3.2 Controlled vocabulary and text words

MEDLINE and Embase (and many other databases) can be searched using a combination of two retrieval approaches. One is based on text words (terms occurring in the title, abstract or other relevant fields) in a record. The other is based on standardized subject terms assigned to the
record by indexers (specialists who appraise the article/reference and describe it by assigning terms from a specific thesaurus or controlled vocabulary) or automatically using automated indexing. Standardized subject terms are useful because they provide a complementary way of retrieving records that may use different text words to describe the same concept and because they can provide information beyond that which is contained in the words in the title and abstract. Therefore, each concept of a robust search strategy should consist of text words together with subject terms, if the latter are available in the respective database.

It is mandatory, for Cochrane Reviews of interventions, to identify appropriate controlled vocabulary (e.g. MeSH, Emtree, including ‘exploded’ terms) (see below for definition of ‘exploded’ terms (MECIR C33)). When searching for studies for a systematic review, however, the extent to which subject terms are applied to references should be viewed with caution. Authors may not describe their methods or objectives well and indexers are not always experts in the subject areas or methodological aspects of the records that they are indexing. In those cases where subject terms are applied as a result of automated/machine indexing, this may not be as accurate as human indexing. In addition, the available indexing terms might not correspond to the terms the searcher wishes to use. It is, therefore, mandatory, for Cochrane Reviews of interventions, to identify appropriate free-text terms (considering, for example, spelling variants, synonyms, acronyms, truncation and proximity operators (MECIR C33)). This is especially important, as the indexing process in databases takes time (ranging from a few weeks to several months until a reference is fully indexed). Therefore, very current references might not yet be indexed and will consequently not be retrieved when using controlled vocabulary alone. Consideration should be given to searching indexed records and non-indexed/in-process records separately in databases such as MEDLINE and Embase which include both indexed and non-indexed content.

The approaches for identifying text words and controlled vocabulary to combine appropriately within a search strategy are presented in the following two sections and can generally be described as being subjective. Text mining is an emerging approach to identify terms in a more objective way, based on a set of relevant records on the topic (see Section 3.2.3 on text mining for term selection). Another objective method is based on similarity calculations derived from one or several known relevant articles. In MEDLINE, having identified a key article, additional relevant articles can be located by using the ‘Find Similar’ option in Ovid or the ‘Similar articles’ option in PubMed. The value of using a complementary search approach such as this feature, which is independent of the searcher’s expertise, has been described (Sampson et al 2016).

3.2.1 Identifying relevant controlled vocabulary
In order to identify as many relevant records as possible, searches should include subject terms selected from the controlled vocabulary or thesaurus (‘exploded’ where appropriate - see below for definition of ‘exploded’ terms). The controlled vocabulary search terms for MEDLINE (Medical Subject Headings, known as MeSH) and Embase (Emtree) are not identical, and neither is the approach to indexing. For example, the pharmaceutical or pharmacological aspects of an Embase record are generally indexed in greater depth than the equivalent
MEDLINE record, and in recent years Elsevier has increased the number of index terms assigned to each Embase record. Searches of Embase may, therefore, retrieve additional articles that were not retrieved by a MEDLINE search, even if the records were present in both databases. The converse also applies in that MEDLINE records available in Embase, which are not also indexed by Elsevier for Embase, are indexed differently in Embase than they were originally in MEDLINE, as the MeSH terms are replaced in Embase by Emtree terms. Thus, search strategies need to be customized for each database and should ideally be run in the original database whenever possible.

Most database interfaces offer a browsing option to show the preferred subject headings. For example, interfaces to MEDLINE will usually permit browsing the Medical Subject Headings (MeSH) so that the term definition (Scope Note) and its synonyms and related terms can be identified and assessed for relevance. Additional controlled vocabulary terms should be identified using the search tools provided with the database, such as the ‘Permutted Index’ or ‘Map Term’ under ‘Search Tools’ in Ovid or the ‘MeSH Database’ option in PubMed. As well as searching the controlled vocabulary lists, it is also common practice to identify subject headings from known relevant records. A tool which can help displaying and comparing the subject terms assigned to MEDLINE records is the ‘Yale MeSH Analyzer’ ([https://mesh.med.yale.edu/](https://mesh.med.yale.edu/)) (Hocking 2017).

Many database thesauri offer the facility to ‘explode’ subject terms to include more specific terms automatically in the search. For example, a MEDLINE search using the MeSH term BRAIN INJURIES, if exploded, will automatically search not only for the term BRAIN INJURIES but also for the more specific term SHAKEN BABY SYNDROME. As articles in MEDLINE on the subject of shaken baby syndrome should only be indexed with the more specific term SHAKEN BABY SYNDROME and not/not also with the more general term BRAIN INJURIES, it is important that MeSH terms are ‘exploded’ wherever appropriate, in order not to miss relevant records. It is equally important, however, that MeSH terms are not ‘exploded’ where this is inappropriate, in order not to add irrelevant records unnecessarily. The same principle applies to Emtree when searching Embase and also to several other databases. For further advice on this topic, review authors should consult a Cochrane Information Specialist, or other medical/healthcare librarian or information specialist.

A second option which can be applied to subject terms, is restricting the term to ‘Major Topic’ (in Ovid this feature is called ‘focus’). When this feature is used, articles are only retrieved where the subject term has been assessed during indexing as reflecting one of the article’s major topics. This is, therefore, a precision-maximizing feature and is not generally recommended in the context of searching for studies for systematic reviews, as it compromises sensitivity.

It is particularly important in MEDLINE to distinguish between Publication Type terms and other related MeSH terms. For example, a report of a randomized trial should be indexed in MEDLINE with the Publication Type term ‘Randomized Controlled Trial’ whereas an article about randomized controlled trials should be indexed with the MeSH term RANDOMIZED
CONTROLLED TRIALS AS TOPIC (note the word TRIALS in the latter is plural). The same applies
to other indexing terms for other trials, reviews and meta-analyses. It should be noted that this
distinction was also introduced into Embase for records added from 2011 onwards. The Emtree
term ‘randomized controlled trial’ is used to describe the publication type of the record,
whereas the Emtree term ‘randomized controlled trial (topic)’ is used for records that discuss
randomized trials, but are not original reports of randomized trials. Prior to 2011, the Emtree
term ‘randomized controlled trial’ was used to index both the publication type of the record
and for records that discussed randomized trials as a topic.

Review authors should assume that earlier articles are even harder to identify than recent
articles. For example, abstracts are not included in MEDLINE for most articles published before
1976 and, therefore, text word searches will only apply to titles. In addition, few MEDLINE
indexing terms relating to study design were available before the 1990s, so text word searches
relating to study design are necessary to retrieve older records.

3.2.2 Identifying relevant text words

Relevant text words (i.e. free-text terms) can be identified by checking the terms used in the
title, abstract and other relevant fields (e.g. author keywords) of a sample of relevant
references. It is important to be aware of the fact that natural language allows concepts to be
expressed in different words. It is essential, therefore, to look up synonyms for each concept
describing the review topic. Medical dictionaries can be used to clarify definitions and identify
synonyms. The MeSH database also offers both definitions (Scope Notes) and a listing of
synonyms and related terms for each MeSH term (‘Entry terms’), which lists different terms
being used for a concept. Likewise, Elsevier’s Emtree thesaurus for Embase also lists synonyms
for each term. Synonyms of pharmaceutical substances can be effectively searched via
consists of checking search strategies from other systematic reviews on a similar topic.

3.2.3 Text mining for term selection

Text mining techniques are of increasing interest in the conduct of systematic reviews
generally and have been the subject of a number of helpful reviews ([O’Mara-Eves et al 2015],
[Paynter et al 2016], [Stansfield et al 2017], [Kohl et al 2018], [Adam et al 2022], [Adam and Paynter
2023]). Text mining encompasses a range of statistical approaches to textual analysis including
simple frequency analysis of words and phrases within records, visual presentations of the
inter-relationships between concepts in a literature (corpus) and the development of complex
interrogation rules to identify relevant records from a corpus of records ([O’Mara-Eves et al
2015], [Paynter et al 2016], [EUnetHTA JA3WP6B2-2 Authoring Team 2019], [Haddaway et al 2020]).
The value of text mining can lie in its ability to process large volumes of records objectively, to
assist with concept identification and to interrogate large numbers of records from many
databases using a single search process. At present, there are no free to access tools that can
fully automate the design and running of searches across several databases and export results
into one file, but parts of the strategy design process can benefit from text mining techniques
combined with traditional searching approaches.
Text mining software can be used to identify potential keywords, phrases and subject terms from within a set of relevant records. Various software packages are listed in the Systematic Review Toolbox (http://systematicreviewtools.com/).

Software tools such as PubMed PubReMiner (https://hgserver2.amc.nl/cgi-bin/miner/miner2.cgi) analyse the results of searches conducted in PubMed and present the words within records in order of frequency. This can aid the identification of terms, synonyms and abbreviations to test out in strategies. For databases other than MEDLINE (PubMed) frequency analysis software such as Voyant Tools (https://voyant-tools.org/) will provide similar frequency analyses or bibliographic reference software such as EndNote (https://endnote.com/) can be used with any database records (McGowan 2021). In EndNote, frequency analysis can be achieved by using the Term Lists and the Subject Bibliography option (detailed guidance at https://sites.google.com/york.ac.uk/yhectrainingpages/home/endnote-for-frequency-analysis).

A tool to assist with identifying relevant MeSH headings is available on the MeSH on Demand website (https://www.nlm.nih.gov/mesh/MeSHonDemand.html): it is possible, for example, to paste in a Cochrane protocol and receive suggestions of MeSH terms that relate to the topics within the text.

Software tools to assist in identifying phrases and words within proximity to each other are also available in Voyant Tools, Termine (http://www.nactem.ac.uk/software/termine/) and many other packages.

A recent analysis of selected tools recommends Text Analyzer, and the Yale MeSH Analyzer as “extremely useful” tools for term identification, and rates Anne O’Tate, PubMed PubReMiner and Voyant as “useful” tools (O’Keefe et al 2023). This analysis favours ease of use over functionality, so users seeking expert functionality may wish to explore other tools which are rated lower in this article.


Text mining has also been used to develop methodological search filters, including the Cochrane Highly Sensitive Search Strategies for MEDLINE and Embase (Glanville et al 2006, Glanville et al 2019b) and a filter to identify overviews of systematic reviews in MEDLINE (Lunny et al 2015). Researchers are also exploring machine learning approaches to converting searches in one database to search in very different databases, such as converting PubMed searches to interrogate records in ClinicalTrials.gov (Lanera et al 2018).
Text mining may be particularly helpful when developing strategies for complex topics. Software such as VOSviewer (https://www.vosviewer.com/) can accept large numbers of records, analyse the co-occurrence of terms within records and show relationships between themes in a body of records visually. This can help with identifying, grouping and combining concepts when building strategies for complex topics (Balan et al 2014, EUnetHTA JA3WP6B2-2 Authoring Team 2019).

Text mining and machine learning tools available free of charge on the Internet can also assist with identifying additional relevant studies. Tools such as Medline Ranker (http://cbdm-01.zdv.uni-mainz.de/~jfontain/), BioReader 1.2 (https://services.healthtech.dtu.dk/services/BioReader-1.2/) and LitSuggest (https://www.ncbi.nlm.nih.gov/research/litsuggest/) can rank search results in order of similarity to known relevant records specified by the searcher (Fontaine et al 2009, Allot et al 2019, Simon et al 2019, Zhang et al 2022). Information specialists report using unsupervised machine learning with the DoCTER site (https://www.icf-docter.com/) to “get quick, data-driven insights into a set of search results” (Cawley 2022). DoCTER helped the information specialists to identify concepts to exclude from searches and to identify a priority set of studies within a larger set of results. There are many other tools available to identify additional relevant studies based on known relevant records (seeds) which make use of algorithms that seek studies that are similar to seed studies (Kreutz and Schenkel 2022). These include the “Similar articles” option within PubMed and resources that search for similar sentences within a large corpus (which can include full text documents), such as LitSense (https://www.ncbi.nlm.nih.gov/research/litsense/) or Elicit (https://elicit.org/) (Allot et al 2019).

As well as ready-to-use internet tools, researchers are creating software tools to carry out specific information retrieval tasks which can be run in R such as litsearchr (https://elizagrames.github.io/litsearchr/) (Crisan et al 2019, Grames et al 2019, McGowan 2021). R code and tools in other programming languages can be accessed from public resources such as GitHub (https://github.com/) (Mesgarpour et al 2016). Using these tools may require some knowledge of programming languages or how to download and run the tools. The advantage of many of these tools is that they offer searchers more control over text analyses and more sophisticated functions than the easy to use “off the shelf” tools described above. Developing new tools will typically require a knowledge of R or programming languages.

More sophisticated text mining software which permits the development of rules for interrogating large sets of records offers opportunities for information specialists and other interested researchers to create searches across large databases containing results from many different databases and can also make use of the semantic relationships within texts to offer more precise searching. The challenges of using more sophisticated techniques include the need to acquire a working knowledge of rule building, parts of speech, ontologies and algorithms. GATE (https://gate.ac.uk/) open-source software is one example of more
sophisticated text mining software which allows searchers to break down text and build new rules, to explore relationships within texts. Learning to use the software efficiently and effectively requires some investment in training and the acquisition of experience.

Instead of using text mining tools to identify search terms and build strategies, researchers are exploring using machine learning software as an alternative to the typical approach to searching databases with detailed search strategies. If machine learning software can be trained to identify relevant records, then a sensitive search approach could be used to identify records from a series of databases or large internet resources such as Dimensions AI (https://www.dimensions.ai/) or OpenAlex (https://openalex.org/). The records could then be processed using machine learning software to identify relevant studies. This means less time might be spent in searching, with searches being very broad (highly sensitive) rather than detailed and relatively focused on the search topic. More time might be spent in training software to recognize relevant records. This approach is already being used by health technology assessment teams and seems to be of particular interest in the context of updating reviews (Muller et al 2021, Shemilt et al 2021, Stansfield et al 2022). The COVID-19 pandemic has been a recent key testbed for the development of resources using combinations of text mining and machine learning (Wang and Lo 2021). Examples of resources built with automated techniques include the Cochrane COVID-19 Study Register (https://covid-19.cochrane.org/) (Shemilt et al 2022) and the Epistemonikos L-OVE (Living OVerview of Evidence) platform (https://iloveevidence.com/) (Metzendorf et al 2023).

Text mining has the potential to involve the acquisition and interrogation of large volumes of search results, so it is important to be aware of both licensing and copyright issues involved in handling large sets of records (Sag 2019).

Text-mining tools have great potential but there are many variants and options to choose from and little guidance about what works best and when and for which questions. There is a need for more case studies and for more parallel research to show where benefits may lie. Text mining carries with it challenges in terms of documentation of the processes used and there is little guidance available on how best to report the use of text mining for strategy development.

There is growing interest in the use of ChatGPT and similar artificial intelligence chatbots, built on Large Language Models, as tools to assist in systematic review processes. Research on the value and role of these tools in the search process is likely to emerge over the coming months and the next update of this online Technical Supplement may allow a clearer assessment of its role. In the meanwhile, ChatGPT or similar tools might be used cautiously as a further search approach, in addition to the traditional search methods described in this Handbook.

### 3.3 Synonyms, related terms, variant spellings, truncation and wildcards

In order to be as comprehensive as possible, it is necessary to include a wide range of free-text terms for each of the concepts selected. This might include the use of truncation and wildcards.
It is mandatory, for Cochrane Reviews of interventions, to identify appropriate spelling variants, synonyms, acronyms and truncation (MECIR C33). For example:

- **synonyms**: ‘pressure sore’ OR ‘decubitus ulcer’;
- **related terms**: ‘brain’ OR ‘head’; and
- **variant spellings**: ‘tumour’ OR ‘tumor’.

Database interfaces offer functionality to capture these variations through truncation and wildcards. For example:

- **truncation**: random* (for random or randomised or randomized or randomly, etc.); and
- **wildcard**: wom?n (for woman or women).

These features vary across different database interfaces, especially with respect to truncation length (e.g. number of characters) and position (e.g. mid-word or end-of-word), and should be checked carefully before adapting a search strategy to a different database and/or interface from that for which it was originally designed. For further details refer to the respective database help files. It should also be noted that many service providers incorporate fuzzy logic searching into their search interfaces and this automatically includes variant endings by default including singular and plural variants.

### 3.4 Boolean operators (AND, OR and NOT)

Boolean operators are used to join together the search terms within a search strategy. The most widely used Boolean operators are:

- **AND**: combines *different concepts* to make a set of results that is usually smaller than the smallest concept (i.e. terms from *all* concepts need to be present in records for them to be retrieved);
- **OR**: gathers terms *within a concept* and this usually makes the set of results larger (i.e. at least one term needs to be present in records for them to be retrieved); and
- **NOT**: excludes terms or concepts (one term or concept can be excluded from the set of results and the set will usually reduce in size – but see caveats below).

Generally speaking, a search strategy should build up the controlled vocabulary terms, text words, synonyms and related terms for each concept (such as the intervention), one concept at a time. Terms within a concept should normally be combined with the Boolean ‘OR’ operator: see demonstration search strategies in Box 3.h and Box 3.i. This means records will be retrieved that contain at least one of these search terms. Sets of terms should usually be developed for the different concepts being searched such as the healthcare condition and
intervention(s) with or without the study design. These two/three concepts (sets of terms) can then be combined using the ‘AND’ operator. This combination step results in a set of records that are likely to address both the health condition of interest and the intervention(s) to be evaluated, together with the appropriate study design, if study design was also included as a concept (see Figure 3.a). It is mandatory, for Cochrane Reviews of interventions, to ensure correct use of the ‘AND’ and ‘OR’ operators (MECIR C32).

A note of caution about this approach is warranted. If a record does not contain at least one term from each of these two or three sets, it will not be identified. For example, if an index term has not been added to the record for the intervention and the intervention is not mentioned in the title or abstract, the record would be missed by the strategy. The best approach is to begin with as few concepts as possible and only add additional concepts if record numbers are unmanageable. So a search might begin with only one concept, and the study design concept might only be added if essential. Note that for searches in the Cochrane Central Register of Controlled Trials (CENTRAL), where all records should refer to controlled trials, the study design concept should not be included in the search strategy.

The ‘NOT’ operator should be avoided where possible to avoid inadvertently removing from the search set any records that might be relevant. For example, when searching for records indexed as female, the use of ‘NOT male’ would remove any record that was about both males and females. NOT can be used in some situations where care is taken to ensure that relevant records are not lost, for example in the animal exclusion algorithm used within the MEDLINE, Embase and CINAHL search filters to identify RCTs (see Section 3.6 and subsections).

Searches to identify studies for Cochrane Reviews can sometimes be extremely long, often including over 100 search lines. It can be tedious to type in the combinations of these search sets, for example as ‘#1 OR #2 OR #3 OR #4 …. OR #100’. Some service providers offer alternatives to this. For example, in CENTRAL and Ovid it is possible to combine sets using the syntax (Cochrane Information Specialist Support Team -#100) or ‘or/1-100’ respectively. For those service providers where this is not possible, it has been recommended that the search string above could be typed in full and saved, for example, as a Word document and the requisite number of combinations copied and pasted into the search as required. Alternatively, the search string could be copied from another search strategy, checking carefully for any typographical errors before use. Having created/identified the string with the # symbols as above, a second string can be generated by globally replacing the # symbol with nothing to create the string ‘1 OR 2 OR 3 OR 4 …. OR 100’ to be used for those service providers where the search interface does not use the # symbol.
Figure 3.a Combining concepts as search sets

3.5 Proximity operators (NEAR, NEXT and ADJ)

Proximity operators identify search terms which are near to each other but not necessarily directly adjacent to each other. Where the operator dictates that the search terms must be directly adjacent to each other, they are often referred to as adjacency operators, e.g. phrase searching. It is mandatory, for Cochrane reviews of interventions, to ensure that proximity operators are used appropriately (MECIR C33). Use of proximity operators helps to ensure that searches are more sensitive than would be the case with direct adjacency or phrase searching,
and can also facilitate ease of searching where there are multiple possible variations of a phrase which would otherwise need to be typed in full.

The following proximity and adjacency operators are illustrated with reference to the Cochrane Library.

**NEXT**

The Cochrane Library uses the proximity operator ‘NEXT’ to identify search terms which are directly adjacent to each other and in the specified order. For example, diabetes NEXT screening retrieves ‘diabetes screening’, but not ‘screening diabetes’.

‘NEXT’ functions in the Cochrane Library in the same way as searching for phrases within quotation marks such as “diabetes screening”. Use ‘NEXT’ for including truncation ‘*’ or wildcards ‘?’ in a phrase, such as ‘diabet* NEXT screen*’.

**NEAR**

The Cochrane Library uses the operator ‘NEAR/n’ to search for search terms within a specified number of words, where n specifies the maximum number of words either search term is from the other search term in any order. For example,

- diabetes NEAR/1 screening retrieves ‘diabetes screening’ and ‘screening diabetes’
- diabetes NEAR/2 screening retrieves ‘diabetes x screening’ and ‘screening x diabetes’ where x is the maximum number of intervening words
- diabetes NEAR/3 screening retrieves ‘diabetes x x screening’ and ‘screening x x diabetes’ where x is the maximum number of intervening words

If using only NEAR, with no number specified, then this defaults to a maximum of 6 words in the Cochrane Library. Thus ‘diabetes NEAR screening’ retrieves ‘diabetes x x x x x x screening’ and ‘screening x x x x x x diabetes’.

**Syntax variation between databases**

Other database interfaces use different operators, for example, ‘Nn’ in the EBSCOhost interface or ‘ADJn’ in the Ovid interface. Links to help pages on proximity operators for each of the main database providers are detailed at the end of this section.

It is important to note that interfaces also vary in how the number n relates to the specified search terms. In the Cochrane Library, Embase.com and Ovid interfaces n specifies the maximum number of words that either search term is from the other search term, i.e. to find a maximum of x words between two search terms n should equal x + 1. In the EBSCOhost, ProQuest, Scopus and Web of Science interfaces n specifies the maximum number of words between the specified search terms, i.e. to find a maximum of x words in between two search terms.
terms \( n \) should equal \( x \). For example, if \( n \) is set to 2 it functions as shown below in the Ovid and EBSCOhost interfaces, respectively, where \( x \) is an intervening word:

- diabetes N2 screening retrieves ‘diabetes \( x \) screening’ and ‘screening \( x \) diabetes’ (EBSCOhost) where \( x \) is the maximum number of intervening words

- diabetes ADJ2 screening retrieves ‘diabetes \( x \) screening’ and ‘screening \( x \) diabetes’ (Ovid) where \( x \) is the maximum number of intervening words

If \( n \) is set to 1 in the Ovid interface it functions as shown below:

- diabetes ADJ1 screening retrieves ‘diabetes screening’ and ‘screening diabetes’

Searching using ADJ in the Ovid interface without specifying \( n \) operates in the same way as NEXT in the Cochrane Library, i.e. the search terms are retrieved but only in the specified order.

When searching using two or more search terms without quotation marks in EBSCO databases, the search terms are automatically combined using the proximity setting N5. This can be overridden by placing the terms in quotation marks, using a different proximity operator value, or combining the search terms using a Boolean operator.

**Proximity operators in PubMed**

Proximity search capability was recently added to PubMed (US National Library of Medicine 2022). To carry out proximity searching in PubMed, the search should be structured as follows:

"search terms" [field:~N]

- Search terms = two or more terms enclosed within double quotation marks
- Field = the search field within which the terms should appear (this is limited to either Title or Title/Abstract fields)
- N = maximum number of words which can appear between the specified search terms

For example, to search PubMed for records where the words “hip” and “pain” appear with no more than two words in between them in the Title/Abstract field, use the following search:

"hip pain"[Title/Abstract:~2]

It is not possible to use the truncation operator (*) with the proximity search function in PubMed. It is also not possible to use phrase searching with the proximity operator function, i.e. you cannot specify that a phrase should appear next to another search term or phrase with a maximum number of words in between. More detail on using the proximity operator function in PubMed is available [here](#).
PubMed does not support phrase searching for phrases which are not in the PubMed phrase index. To search for a phrase which is not in the phrase index, use a proximity operator setting of 0 to search for the required phrase, e.g. "cognitive impairment in multiple sclerosis" [Title/Abstract:~0].

**Retaining the order of search terms**

As noted above, the NEAR operator in the Cochrane Library and the equivalent operators used in other interfaces identify the specified search terms in any order. There is no option in the Cochrane Library for specifying the maximum number of words between search terms and retaining the specified order of the search terms. Some database providers do offer this option. For example, the EBSCOhost and ProQuest interfaces retain the specified order of search terms when using the ‘Wn’ and ‘pre/n’ operators, respectively, as shown below:

- diabetes W2 screening retrieves ‘diabetes x x screening’ where x is the maximum number of intervening words (EBSCOhost)
- diabetes pre/2 screening retrieves ‘diabetes x x screening’ where x is the maximum number of intervening words (ProQuest)

**Help pages for proximity operators**

Listed below are help links on how to use proximity operators produced by the main database providers. Some of these links go directly to the proximity operators help section and others require searching for the proximity operators section within them.

The Cochrane Library databases


EBSCO databases


Ovid databases (scroll down to Adjacency/Defined Adjacency)

[https://ospguides.ovid.com/OSPguides/medline.htm](https://ospguides.ovid.com/OSPguides/medline.htm)

ProQuest databases


PubMed database (Automatic Term Mapping)


PubMed database (Searching for a Phrase)
3.6 Search filters

This section should be read in conjunction with Chapter 4, Section 4.4.7.

3.6.1 The Cochrane Highly Sensitive Search Strategies for identifying randomized trials in MEDLINE

The first Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE was designed by one of the authors (CL) and published in 1994 (Dickersin et al 1994). This strategy was thereafter published in subsequent editions of this Handbook and has been adapted and updated as necessary over time. The Cochrane Highly Sensitive Search Strategies for MEDLINE, in subsequent sections, are adapted from strategies first published in 2006 as a result of a frequency analysis of MeSH terms and free-text terms occurring in the titles and abstracts of MEDLINE-indexed records of reports of randomized trials (Glanville et al 2006), using methods of search strategy design first developed by the authors to identify systematic reviews in MEDLINE (White et al 2001).

Two strategies are offered: a sensitivity-maximizing version and a sensitivity- and precision-maximizing version. It is recommended that searches for trials for inclusion in Cochrane Reviews begin with the sensitivity-maximizing version in combination with a highly sensitive subject search. If this retrieves an unmanageable number of references the sensitivity- and precision-maximizing version should be used instead. See Sections 2.1.1, 2.1.2, 2.2.1 and 2.2.2 for details as to how these search strategies and others have been run centrally in Cochrane over the years and relevant records included in CENTRAL, to avoid unnecessary duplication of effort.

The strategies have been updated pragmatically, to reflect changes in search syntax and changes in indexing policy introduced by the US National Library of Medicine since the original analysis. These changes include:

- the change of the MeSH term CLINICAL TRIALS to CLINICAL TRIALS AS TOPIC;
- no longer assigning ‘Clinical Trial’ as a Publication Type to all records indexed with ‘Randomized Controlled Trial’ or ‘Controlled Clinical Trial’ as a Publication Type; and
• the introduction of two more specific (i.e. narrower) headings to the Publication Type RANDOMIZED CONTROLLED TRIAL, which means it should now be exploded.

A recent performance review has demonstrated that the Cochrane RCT filter continues to rank highly in terms of sensitivity (Glanville et al 2020). The strategies are given in Box 3.a and Box 3.b for PubMed and in Box 3.c and Box 3.d for Ovid.

The strategies below are based on data derived from MEDLINE-indexed records and were designed to be run in MEDLINE. These strategies were not specifically designed to retrieve non-MEDLINE records in PubMed or, for example, those records in the Ovid segments: ‘Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations’. However, as noted above, the Cochrane RCT filter performed highly in terms of sensitivity in a recent performance test suggesting that the concerns around performance in unindexed studies may be allayed (Glanville et al 2020). However, for those who do have concerns that the filters may miss unindexed studies, the filters could be run in the ‘Ovid MEDLINE(R) ALL/PubMed(R) 1946 to Present’ Ovid segment and the status field (ST) limits below could be used to isolate the MEDLINE-indexed and the non-indexed records as follows:

• all records in the database: docz.dz.

• MEDLINE status: medline.st. (i.e. MEDLINE-indexed)

• Publisher - ahead of print status: publisher.st.

• In-process & non-indexed citations: ("in data review" or in process or "pubmed not medline").st.

• Pmcbooks: nb$.bk.

The use of the various status limits and how they add up to all records in the entire MEDLINE on Ovid database (generated by the search term docz.dz.) is shown below:

Ovid MEDLINE(R) ALL <1946 to May 02, 2023>

<table>
<thead>
<tr>
<th>#</th>
<th>Searches</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>docz.dz.</td>
<td>35658514</td>
</tr>
<tr>
<td>2</td>
<td>limit 1 to medline</td>
<td>30434206</td>
</tr>
<tr>
<td>3</td>
<td>limit 1 to publisher</td>
<td>317973</td>
</tr>
<tr>
<td>4</td>
<td>limit 1 to (&quot;in data review&quot; or in process or &quot;pubmed not medline&quot;)</td>
<td>4875373</td>
</tr>
</tbody>
</table>
For identifying non-indexed records a range of truncated free-text terms would be required, such as random, placebo, trial, etc., and the search must not be limited to humans (as the records may not yet be indexed as humans).

As discussed in Section 2.1.1, MEDLINE has been searched from 1966 to 2004 inclusive, using previous versions of the Cochrane Highly Sensitive Search Strategy for identifying randomized trials, and more recent MEDLINE records (from 2011) have been searched as part of the current Embase project. All reports of trials identified in these ways (predominantly on the basis of the titles and abstracts only) are now included in CENTRAL (see Sections 2.1.1 and 2.1.2). For further guidance as to the appropriate use of these Highly Sensitive Search Strategies see Section 2.2.2. Alternatively, other search filters for identifying reports of RCTs in MEDLINE can be identified from the InterTASC Information Specialists’ Sub-Group’s Search Filter Resource (https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/home/rcts).

Box 3.a Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); PubMed format

| #1  | randomized controlled trial [pt]                            |
| #2  | controlled clinical trial [pt]                             |
| #3  | randomized [tiab]                                          |
| #4  | placebo [tiab]                                             |
| #5  | drug therapy [sh]                                          |
| #6  | randomly [tiab]                                            |
| #7  | trial [tiab]                                                |
| #8  | groups [tiab]                                               |
| #9  | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8               |
| #10 | animals [mh] NOT humans [mh]                               |
| #11 | #9 NOT #10                                                  |

PubMed search syntax (for Box 3.a above and Box 3.b below):
[pt] denotes a Publication Type term;
[tiab] denotes a word in the title or abstract;

[sh] denotes a subheading;

[mh] denotes a Medical Subject Heading (MeSH) term ‘exploded’;

[mesh:noexp] denotes a Medical Subject Heading (MeSH) term not ‘exploded’;

[ti] denotes a word in the title.

Box 3.b Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision); PubMed format

| #1     | randomized controlled trial [pt] |
| #2     | controlled clinical trial [pt]   |
| #3     | randomized [tiab]                |
| #4     | placebo [tiab]                  |
| #5     | clinical trials as topic [mesh:noexp] |
| #6     | randomly [tiab]                 |
| #7     | trial [ti]                      |
| #8     | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 |
| #9     | animals [mh] NOT humans [mh]    |
| #10    | #8 NOT #9                       |

The search syntax is explained above under Box 3.a

Box 3.c Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2023 revision); Ovid format

1 exp randomized controlled trial/
2 controlled clinical trial.pt.
3 randomized.ab.
4 placebo.ab.
5 drug therapy.fs.
Ovid search syntax (for Box 3.c above and Box 3.d below):
exp denotes a Medical Subject Heading (MeSH) term ‘exploded’;
.pt. denotes a Publication Type term;
.ab. denotes a word in the abstract;
.fs. denotes a ‘floating’ subheading, that is a subheading irrespective of the MeSH term to which it is attached;
.sh. denotes a Medical Subject Heading (MeSH) term not ‘exploded’;
.ti. denotes a word in the title.

Box 3.d Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximizing version (2023 revision); Ovid format
The search syntax is explained above under Box 3.c.

3.6.2 Search filters for identifying randomized trials in Embase
As discussed in Section 2.1.2, Embase has been searched with various filters from 1980 to date (and from 1974 to 1979 for some search terms), and records of reports of trials (predominantly based on screening the titles and abstracts only) have been included in CENTRAL. Cochrane funded the development of a highly sensitive search strategy for identifying reports of controlled trials in Embase (Glanville et al 2019b). This search filter was designed for the Embase database via the Ovid interface and was developed, tested and validated in 2016.

After the development of the filter, the Cochrane Centralized Search Service (CSS) decided to move to conducting regular searches for reports of RCTs and CCTs using the Embase.com interface, maintained by Elsevier. This move required a translation of the Ovid Embase RCT filter (Glanville et al 2019b). Variations of this filter have been used over time to identify reports of controlled trials in Embase for inclusion in CENTRAL. For the current version of the Embase.com filter used by Cochrane for identifying trials for CENTRAL, see the ‘How CENTRAL is created’ file at https://www.cochranelibrary.com/central/central-creation. The filters described above were optimized for identifying reports of trials for CENTRAL and were not optimized for use by individuals searching Embase to identify RCTs. A proposed filter for researchers for identifying trials in Embase.com is shown in Box 3.e and the Ovid version is shown in
Box 3.f below. This filter was updated in April 2023 to reflect the addition of more specific (i.e. narrower) Emtree terms to the ‘Randomized controlled trial’ Emtree heading. The revision has involved exploding that heading in the two lines where it is used in the filter. Alternatively, other search filters for identifying reports of RCTs in Embase can be identified from the InterTASC Information Specialists’ Sub-Group’s Search Filter Resource (https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/home/rcts).

Box 3.e Cochrane Highly Sensitive Search Strategy for identifying controlled trials in Embase: (2023 revision); Embase.com format (Glanville et al 2019b)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>‘randomized controlled trial'/exp</td>
</tr>
<tr>
<td>2</td>
<td>‘controlled clinical trial'/de</td>
</tr>
<tr>
<td>3</td>
<td>random*:ti,ab,tt</td>
</tr>
<tr>
<td>4</td>
<td>‘randomization'/de</td>
</tr>
<tr>
<td>5</td>
<td>‘intermethod comparison’/de</td>
</tr>
<tr>
<td>6</td>
<td>placebo:ti,ab,tt</td>
</tr>
<tr>
<td>7</td>
<td>(compare:ti,tt OR compared:ti,tt OR comparison:ti,tt)</td>
</tr>
<tr>
<td>8</td>
<td>((evaluated:ab OR evaluate:ab OR evaluating:ab OR assessed:ab OR assess:ab) AND (compare:ab OR compared:ab OR comparing:ab OR comparison:ab))</td>
</tr>
<tr>
<td>9</td>
<td>(open NEXT/1 label):ti,ab,tt</td>
</tr>
<tr>
<td>10</td>
<td>((double OR single OR doubly OR singly) NEXT/1 (blind OR blinded OR blindly)):ti,ab,tt</td>
</tr>
<tr>
<td>11</td>
<td>‘double blind procedure’/de</td>
</tr>
<tr>
<td>12</td>
<td>(parallel NEXT/1 group*):ti,ab,tt</td>
</tr>
<tr>
<td>13</td>
<td>(crossover:ti,ab,tt OR ‘cross over’:ti,ab,tt)</td>
</tr>
<tr>
<td>14</td>
<td>((assign* OR match OR matched OR allocation) NEAR/6 (alternate OR group OR groups OR intervention OR interventions OR patient OR patients OR subject OR subjects OR participant OR participants)):ti,ab,tt</td>
</tr>
<tr>
<td>15</td>
<td>(assigned:ti,ab,tt OR allocated:ti,ab,tt)</td>
</tr>
<tr>
<td>16</td>
<td>(controlled NEAR/8 (study OR design OR trial)):ti,ab,tt</td>
</tr>
<tr>
<td>17</td>
<td>(volunteer:ti,ab,tt OR volunteers:ti,ab,tt)</td>
</tr>
</tbody>
</table>
18 ‘human experiment’/de

19 trial:ti,tt

20 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19

21 (((random* NEXT/1 sampl* NEAR/8 (‘cross section*’ OR questionnaire* OR survey OR surveys OR database or databases)):ti,ab,tt) NOT (‘comparative study’/de OR ‘controlled study’/de OR ‘randomised controlled’:ti,ab,tt OR ‘randomly controlled’:ti,ab,tt OR ‘randomly assigned’:ti,ab,tt))

22 (‘cross-sectional study’/de NOT (‘randomized controlled trial’/exp OR ‘controlled clinical study’/de OR ‘controlled study’/de OR ‘randomised controlled’:ti,ab,tt OR ‘randomized controlled’:ti,ab,tt OR ‘control group’:ti,ab,tt OR ‘control groups’:ti,ab,tt))

23 (‘case control*’:ti,ab,tt AND random*:ti,ab,tt NOT (‘randomised controlled’:ti,ab,tt OR ‘randomized controlled’:ti,ab,tt))

24 (‘systematic review’:ti,tt NOT (trial:ti,tt OR study:ti,tt))

25 (nonrandom*:ti,ab,tt NOT random*:ti,ab,tt)

26 ‘random field*’:ti,ab,tt

27 (‘random cluster’ NEAR/4 sampl*):ti,ab,tt

28 (review:ab AND review:it) NOT trial:ti,tt

29 (‘we searched’:ab AND (review:ti,tt OR review:it))

30 ‘update review’:ab

31 (databases NEAR/5 searched):ab


33 (‘animal experiment’/de NOT (‘human experiment’/de OR ‘human’/de))

34 #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33
Embase.com search syntax
/exp denotes an exploded index term (Emtree indexing term);
/de denotes an index term (Emtree indexing term);
:ti denotes a word in the article title;
:ab denotes a word in the abstract;
:tt denotes a word in the original non-English title;
:it denotes a publication type (item type).

The Cochrane Embase RCT filters for Embase.com and Ovid – version for searchers – (2023 revision) are also available from https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/home/rcts/embase-rct-filter.
Box 3.f Cochrane Highly Sensitive Search Strategy for identifying controlled trials in Embase: 2023 revision; Ovid format (adapted from J. Glanville, Foxlee, et al., 2019)

<table>
<thead>
<tr>
<th>Line</th>
<th>Search Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>exp randomized controlled trial/</td>
</tr>
<tr>
<td>2</td>
<td>controlled clinical trial/</td>
</tr>
<tr>
<td>3</td>
<td>random$.ti,ab.</td>
</tr>
<tr>
<td>4</td>
<td>randomization/</td>
</tr>
<tr>
<td>5</td>
<td>intermethod comparison/</td>
</tr>
<tr>
<td>6</td>
<td>placebo.ti,ab.</td>
</tr>
<tr>
<td>7</td>
<td>(compare OR compared OR comparison).ti,ab.</td>
</tr>
<tr>
<td>8</td>
<td>((evaluated OR evaluate OR evaluating OR assessed OR assess) AND (compare OR compared OR comparing OR comparison)).ab.</td>
</tr>
<tr>
<td>9</td>
<td>(open adj label).ti,ab.</td>
</tr>
<tr>
<td>10</td>
<td>(double OR single OR doubly OR singly) adj (blind OR blinded OR blindly)).ti,ab.</td>
</tr>
<tr>
<td>11</td>
<td>double blind procedure/</td>
</tr>
<tr>
<td>12</td>
<td>parallel group$1.ti,ab.</td>
</tr>
<tr>
<td>13</td>
<td>(crossover OR cross over).ti,ab.</td>
</tr>
<tr>
<td>14</td>
<td>((assign$ OR match OR matched OR allocation) adj5 (alternate OR group$1 OR intervention$1 OR patient$1 OR subject$1 OR participant$1)).ti,ab.</td>
</tr>
<tr>
<td>15</td>
<td>(assigned OR allocated).ti,ab.</td>
</tr>
<tr>
<td>16</td>
<td>(controlled adj7 (study OR design OR trial)).ti,ab.</td>
</tr>
<tr>
<td>17</td>
<td>(volunteer OR volunteers).ti,ab.</td>
</tr>
<tr>
<td>18</td>
<td>human experiment/</td>
</tr>
<tr>
<td>19</td>
<td>trial.ti.</td>
</tr>
<tr>
<td>20</td>
<td>or/1-19</td>
</tr>
<tr>
<td>21</td>
<td>(random$ adj samp$ adj7 (&quot;cross section$&quot; OR questionnaire$1 OR survey$ OR database$1)).ti,ab. NOT (comparative study/ OR controlled study/ OR randomi?ed controlled.ti,ab. OR randomly assigned.ti,ab.)</td>
</tr>
<tr>
<td>22</td>
<td>cross-sectional study/ NOT (exp randomized controlled trial/ OR controlled clinical trial/ OR controlled study/ OR randomi?ed controlled.ti,ab. OR control group$1.ti,ab.)</td>
</tr>
<tr>
<td>24</td>
<td>systematic review.ti,ab. NOT (trial OR study).ti.</td>
</tr>
<tr>
<td>25</td>
<td>(nonrandom$ NOT random$).ti,ab.</td>
</tr>
<tr>
<td>26</td>
<td>&quot;random field$&quot;.ti,ab.</td>
</tr>
</tbody>
</table>
(random cluster adj3 samp$l).ti,ab.
(review.ab. AND review.pt.) NOT trial.ti.
"we searched".ab. AND (review.ti. OR review.pt.)
"update review".ab.
(databases adj4 searched).ab.
(rat OR rats OR mouse OR mice OR swine OR porcine OR murine OR sheep OR lambs
OR pigs OR piglets OR rabbit OR rabbits OR cat OR cats OR dog OR dogs OR cattle OR bovine
OR monkey OR monkeys OR trout OR marmoset$1).ti. AND animal experiment/
animal experiment/ NOT (human experiment/ OR human/)
or/21-33
20 NOT 34

**Embase on Ovid search syntax**
exp denotes an Emtree term 'exploded';
/ denotes an Emtree term not ‘exploded’;
.ti,ab. denotes a word in the title or abstract;
.ab. denotes a word in the abstract;
.ti. denotes a word in the title;
.pt. denotes a Publication Type term.

**3.6.3 Search filters for identifying randomized trials in CINAHL versions without full text**
A search filter for identifying randomized trials in the then CINAHL Plus was prepared by the Cochrane Centralized Search Service (CSS) and was published in February 2019 ([Glanville et al 2019a](#)). Note that this search filter is optimized for CINAHL without the full text publications and searchers with access to versions with full text publications should consider additional search approaches to make use of the option to search the full text (see Section 3.6.1 above). The strategy was modified in May 2023 to explode MH randomized controlled trials to reflect NLM’s changes to that heading which were also adopted in CINAHL.

**Box 3.g Cochrane Highly Sensitive Search Strategy for identifying controlled trials in CINAHL EBSCO versions without full text (May 2023 version)**

| S1 | MH randomized controlled trials |
| S2 | MH double-blind studies         |
| S3 | MH single-blind studies         |
| S4 | MH random assignment            |
S5 MH pretest-posttest design
S6 MH cluster sample
S7 TI (randomised OR randomized)
S8 AB (random*)
S9 TI (trial)
S10 MH (sample size) AND AB (assigned OR allocated OR control)
S11 MH (placebos)
S12 PT (randomized controlled trial)
S13 AB (control W5 group)
S14 MH (crossover design) OR MH (comparative studies)
S15 AB (cluster W3 RCT)
S16 MH animals+
S17 MH (animal studies)
S18 TI (animal model*)
S19 S16 OR S17 OR S18
S20 MH (human)
S21 S19 NOT S20
S22 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15
S23 S22 NOT S21

Key

MH CINAHL subject heading
+ explode subject heading
AB Word in abstract
TI Word in title
random* Truncated word
3.7 Demonstration search strategies

Box 3.g provides a demonstration search strategy for CENTRAL for the topic ‘treating breast cancer with tamoxifen’. Note that it includes topic terms only and there is no limiting to humans only (a randomized trial filter is not appropriate for CENTRAL; nor is limiting to humans as CENTRAL contains only reports of trials in humans). The strategy is provided for illustrative purposes only: searches of CENTRAL for studies to include in a systematic review would have many more search terms for each of the concepts.

Box 3.h provides a demonstration search strategy for MEDLINE (Ovid format) for the topic ‘treating breast cancer with tamoxifen’. Note that both topic terms and a randomized trial filter are used for MEDLINE. The search is limited to humans. The strategy is provided for illustrative purposes only: searches of MEDLINE for studies to include in a systematic review would have many more search terms for each of the concepts.

**Box 3.h Demonstration search strategy for CENTRAL, for the topic ‘treating breast cancer with tamoxifen’**

<table>
<thead>
<tr>
<th>#</th>
<th>Search Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>[mh &quot;breast neoplasms&quot;]</td>
</tr>
<tr>
<td>#2</td>
<td>(breast NEAR cancer*):ti,ab,kw</td>
</tr>
<tr>
<td>#3</td>
<td>(breast NEAR neoplasm*):ti,ab,kw</td>
</tr>
<tr>
<td>#4</td>
<td>(breast NEAR carcinoma*):ti,ab,kw</td>
</tr>
<tr>
<td>#5</td>
<td>(breast NEAR tumour*):ti,ab,kw</td>
</tr>
<tr>
<td>#6</td>
<td>(breast NEAR tumor*):ti,ab,kw</td>
</tr>
<tr>
<td>#7</td>
<td>#1 OR #2 OR #3 OR #4 OR #5 OR #6</td>
</tr>
<tr>
<td>#8</td>
<td>[mh tamoxifen]</td>
</tr>
<tr>
<td>#9</td>
<td>tamoxifen:ti,ab,kw</td>
</tr>
<tr>
<td>#10</td>
<td>#8 OR #9</td>
</tr>
<tr>
<td>#11</td>
<td>#7 AND #10</td>
</tr>
</tbody>
</table>

Cochrane CENTRAL search syntax for the Cochrane Library via the Wiley interface

mh denotes a MeSH term;
The ‘NEAR’ operator defaults to within six words;

‘*’ indicates truncation

:ti,ab,kw denotes a word or phrase in the title, abstract or keyword field.

**Box 3.i Demonstration search strategy for MEDLINE (Ovid format), for the topic ‘treating breast cancer with tamoxifen’**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>exp randomized controlled trial/</td>
</tr>
<tr>
<td>2</td>
<td>controlled clinical trial.pt.</td>
</tr>
<tr>
<td>3</td>
<td>randomized.ab.</td>
</tr>
<tr>
<td>4</td>
<td>placebo.ab.</td>
</tr>
<tr>
<td>5</td>
<td>drug therapy.fs.</td>
</tr>
<tr>
<td>6</td>
<td>randomly.ab.</td>
</tr>
<tr>
<td>7</td>
<td>trial.ab.</td>
</tr>
<tr>
<td>8</td>
<td>groups.ab.</td>
</tr>
<tr>
<td>9</td>
<td>or/1-8</td>
</tr>
<tr>
<td>10</td>
<td>exp animals/ not humans/</td>
</tr>
<tr>
<td>11</td>
<td>9 not 10</td>
</tr>
<tr>
<td>12</td>
<td>exp Breast Neoplasms/</td>
</tr>
<tr>
<td>13</td>
<td>(breast adj6 cancer$).ti,ab,kf.</td>
</tr>
<tr>
<td>14</td>
<td>(breast adj6 neoplasm$). ti,ab,kf.</td>
</tr>
<tr>
<td>15</td>
<td>(breast adj6 carcinoma$). ti,ab,kf.</td>
</tr>
<tr>
<td>16</td>
<td>(breast adj6 tumour$). ti,ab,kf.</td>
</tr>
<tr>
<td>17</td>
<td>(breast adj6 tumor$). ti,ab,kf.</td>
</tr>
<tr>
<td>18</td>
<td>or/12-17</td>
</tr>
<tr>
<td>19</td>
<td>exp Tamoxifen/</td>
</tr>
</tbody>
</table>
search strategies need to be customized for each database and search interface. Special caution is warranted when adapting a search strategy developed for a specific database in a specific interface to other databases and/or interfaces. This process requires a thorough knowledge of the specifications of both the new database and the new interface, including the controlled vocabulary being used to index the database’s content and the availability of Boolean and proximity operators, as well as the specific syntax for wildcards and truncation and definitions of date fields. These vary across databases and interfaces and need to be taken into account before running a strategy. Searchers should be particularly vigilant with respect to wildcard and truncation symbols, which in some cases have the opposite meaning in different database interfaces. Additionally, a search for health economics in a general healthcare database such as MEDLINE will require different natural language (free-text) terminology/search terms from the terminology required in a specialized economics database. Review authors are, therefore, encouraged to work together with a Cochrane Information Specialist, or other medical/healthcare librarian or information specialist, who can provide advice on the accuracy of adaptations carried out by the review authors themselves or may be able to provide adaptations of the principal, generally MEDLINE, search strategy into the databases and trials registers, which will be searched for the review. Some attempts have been made to simplify through automation the adaptation of search syntax across service providers:

- Bond University Centre for Research in Evidence-Based Practice Systematic Review Accelerator Polyglot application project [http://sr-accelerator.com/#/polyglot](http://sr-accelerator.com/#/polyglot)
None of the above, however, addresses the complexities outlined above regarding differences in natural language (free-text) terminology or controlled vocabulary.

With respect to date fields, the table below indicates the equivalent date fields between Ovid and PubMed. For example, it is important to note that the Publication Date (DP) field in PubMed (for the date that the article was published) is not equivalent to the Year of Publication (YR) field in Ovid MEDLINE – see Table 3.8.a.

For further information on MEDLINE/PubMed date field descriptions see:


For further information on how date fields in Ovid MEDLINE correlate with those in PubMed see:


Table 3.8.a Equivalent date fields between Ovid MEDLINE and PubMed

<table>
<thead>
<tr>
<th>PubMed Search</th>
<th>Ovid MEDLINE Search</th>
</tr>
</thead>
<tbody>
<tr>
<td>(&quot;1950&quot;[Date - Publication]: &quot;2022&quot;[Date - Publication])</td>
<td>Note: Use both YR and EP: 1950:2022.(yr). or 19500101:20221231.(ep).</td>
</tr>
<tr>
<td>(&quot;1950&quot;[Date - MeSH]: &quot;2022&quot;[Date - MeSH])</td>
<td>DA - MeSH date: 19500101:20221231.(da).</td>
</tr>
<tr>
<td>(&quot;1950&quot;[Date - Entrez]: &quot;2022&quot;[Date - Entrez])</td>
<td>EZ - Entrez date: 19500101:20221231.(ez).</td>
</tr>
<tr>
<td>(&quot;1950&quot;[Date - Create]: &quot;2022&quot;[Date - Create])</td>
<td>DT - Create date: 19500101:20221231.(dt).</td>
</tr>
<tr>
<td>(&quot;1950&quot;[Date - Completion]: &quot;2022&quot;[Date - Completion])</td>
<td>ED - Entry date: 19500101:20221231.(ed).</td>
</tr>
</tbody>
</table>
3.9 Identifying fraudulent studies, other retracted publications, errata and comments: further considerations

This section should be read in conjunction with Chapter 4, Section 4.4.6. It is mandatory, for authors of Cochrane Reviews of interventions, to examine any relevant retraction statements and errata for information (MECIR C48). Identifying retraction statements and published errata or comments (and their associated original retracted articles or corrected articles) can help to avoid errors that impact on the overall estimates in systematic reviews. It is essential at the original search stage to ascertain whether any retractions or errata have been published for studies to be included in the original review and also at the update stage to ascertain whether any retractions or errata have been published subsequently for studies previously included in the original review.

Reports of studies indexed in MEDLINE that have been retracted (as fraudulent or for other reasons) will have the Publication Type term ‘Retracted Publication’ added to the record (since 1989). The article giving notice of the retraction (the retraction notice) will have the Publication Type term ‘Retraction of Publication’ assigned (since 1991).

How to search for retraction notices and retracted publications in Ovid MEDLINE:

- retracted publication.pt. or retraction of publication.pt.

How to search for retraction notices and retracted publications in PubMed:

- retracted publication [pt] OR retraction of publication [pt]

The above searches should be supplemented with a free-text search of both of the terms ‘retracted’ and ‘retraction’ limited to the title fields, to pick up records not (yet) indexed as such but this will inevitably result in false positives, i.e. irrelevant records.

Retraction notices indexed in Embase until April 2017 were identified by the Publication Type ‘erratum’ and were additionally indexed with the Preferred Term ‘retracted article’. There was no link, prior to April 2017, back from the retraction notice to the original retracted article, as there is in MEDLINE.

How to search for retraction notices and retracted publications in Ovid Embase:

- Erratum.pt. or Retracted article/ or Tombstone.pt. or yes.ne.

As above for MEDLINE, the above search in Embase should be supplemented with a free-text search of both of the terms ‘retracted’ and ‘retraction limited to the title fields, to pick up records not (yet) indexed as such but this will inevitably result in false positives, i.e. irrelevant records.

Prior to any decision being taken to retract an article, articles may be published that refer to an original article and raise concerns of this sort. A new MeSH Publication Type was introduced
in 2018 to cover this: Expression of Concern. This is defined in the Scope Note as: “A notification about the integrity of a published article that is typically written by an editor and should be labelled prominently in the item title. It is the responsibility of the editor to initiate appropriate investigative procedures, discover the outcome of the investigation, and notify readers of that outcome in a subsequent published item. The outcome may require the publication of a retraction notice.”

To search for “expressions of concern” prior to 2018, search for the phrase “expression of concern”.

Search in Ovid, across all dates, as:

expression of concern.pt. or "expression of concern".af.

Search in PubMed, across all dates, as:

"expression of concern"[Publication Type] OR "expression of concern"[All Fields]

As noted above, MEDLINE/PubMed reports of randomized trials that have been retracted and indexed as such in the MEDLINE, will include the ‘Retracted Publication’ term in the Publication Type field (since 1989). This is also the case for those retracted articles in CENTRAL which are sourced from MEDLINE. This is not, however, the case for the majority of records from Embase (prior to 2017) or from other sources.

In addition, articles may have been partially retracted (previously indexed in MEDLINE as Partial Retraction but since 2016 indexed as Erratum), corrected through a published erratum or may have been corrected and re-published in full. It is therefore important to search MEDLINE for the latest version of the citations to the records for the (previously) included studies when updating a review. In some display formats of some versions of MEDLINE the retracted publication, erratum and comment statements are included in the citation data together with the title and are, therefore, highly visible. This is not, however, always the case so care should be taken to ensure that this information is always retrieved in all searches by downloading the appropriate fields together with the citation data.

Retraction Watch is a resource listing retracted publications (since late 2010). Review authors and others interested in keeping abreast of this area can subscribe to their blog by email. They can also search the Retraction Watch blog and archives by category (http://retractionwatch.com/) or search the Retraction Watch Database (http://retractiondatabase.org/), which has over 40,000 entries (as of July 2023). A user guide is available at https://retractionwatch.com/retraction-watch-database-user-guide/. Some reference management and related programmes, such as Edifix, EndNote, LibKey, Papers, and Zotero, link with the Retraction Watch Database to notify the user automatically when a reference to a study matches a retraction in the Retraction Watch Database. Further
information on this functionality is available from the various reference management software providers.

### 3.10 Summary points

- Cochrane Review authors should seek advice from a Cochrane Information Specialist, or other medical/healthcare librarian or information specialist, on designing search strategies.

- Authors of non-Cochrane reviews should seek advice from a medical/healthcare librarian or information specialist, with experience of conducting searches for studies for systematic reviews.

- Avoid too many different search concepts but use a wide variety of synonyms and related terms within each concept.

- Appropriate controlled vocabulary (e.g. MeSH, Emtree, including ‘exploded’ terms) and free-text terms should be identified (considering, for example, spelling variants, synonyms, acronyms, truncation and proximity operators).

- Ensure correct use of the ‘AND’ and ‘OR’ operators.

- Avoid use of the ‘NOT’ operator in combining search sets.

- Specially designed and tested search filters should be used where appropriate including the Cochrane Highly Sensitive Search Strategies for identifying randomized trials in MEDLINE, Embase and CINAHL.

- Do not use filters in pre-filtered databases e.g. do not use a randomized trial or human studies filter in CENTRAL or a systematic review filter in a database consisting solely of systematic reviews.

- For identifying randomized trials in MEDLINE, begin with a highly sensitive search filter such as the sensitivity-maximizing version of the Cochrane Highly Sensitive Search Strategy. If this retrieves an unmanageable number of references, use the sensitivity- and precision-maximizing version instead. (See Sections 2.1.1 and 2.2.2 for details as to how these search strategies have already been run centrally in Cochrane over the years and relevant records included in CENTRAL, to avoid unnecessary duplication of effort.)

- Searches designed for a specific database and service provider will need to be adapted for use in another database or service provider.

- Ensure awareness of any retracted publications (e.g. fraudulent publications), errata and comments.
• Consideration should be given to searching indexed records and non-indexed/in-process records separately in databases such as MEDLINE and Embase which include both indexed and non-indexed content.

4 Managing references

4.1 Reference management software

Reference management software is used to import, de-duplicate, and store references from database searches and searches of other sources. Specially designed bibliographic or reference management software such as EndNote (https://endnote.com/), Mendeley (https://www.mendeley.com/), RefWorks (https://about.proquest.com/en/products-services/refworks) and Zotero (https://www.zotero.org/) is useful and relatively easy to use to keep track of references to and other records of studies (Lorenzetti and Ghali 2013). Reference management software varies in terms of cost, operating system, and ease of database and record sharing, among other characteristics. The choice of which software to use is likely to be influenced by what is available and thus supported at the review author’s institution. There are currently (May 2023) approximately 40 different software tools listed in the reference management section of the Systematic Review Toolbox at: http://systematicreviewtools.com/. For a comparison of several of the main products see https://en.wikipedia.org/wiki/Comparison_of_reference_management_software.

Reference management software usually provides import file formats (import filters) that allow text files exported from sources such as APA PsycInfo, CENTRAL, CINAHL, Embase, MEDLINE, PubMed and others to be imported into the reference management database. Some reference management software can also be used to search sources such as PubMed from within the database of citations and to import retrieved records directly from those sources. Using reference management software to carry out complex searches, such as those for identifying studies for systematic reviews, is, however, discouraged (Gomis et al 2008).

Reference management software facilitates storage of information about the methods and process of a search. For example, unused record fields can be used to store information such as 1) the name of the database or other source details from which a trial record was identified, 2) when and from where a document was ordered and the date of document receipt, 3) when and with whom the search results were shared, and 4) whether the study associated with a record/document was included in or excluded from a review and, if excluded, the reasons for exclusion.

Software is increasingly being developed to manage a range of functions within the systematic review process and many of these products also have some level of reference management capacity. See Chapter 4, Section 4.6.6.1 of the Handbook for a discussion of software that can be used to assist in record screening and selection. Further information about these software tools is available from the Systematic Review Toolbox at http://systematicreviewtools.com/.
4.2 Which fields to download

In addition to the fields that are essential for identifying a reference (e.g. author, title, source, year) several additional key fields should be considered for downloading from databases where they are available. Some of these key fields are listed below. The list below is intended, where possible, to be generic across databases. For the full range of fields in PubMed, see https://www.nlm.nih.gov/bsd/mms/medlineelements.html.


**Abstract:** abstracts can be used to eliminate clearly irrelevant reports, obviating the need to obtain the full text of those reports or to return to the bibliographic database at a later time.

**Accession number/unique identifier:** it is advisable to allocate an unused field or fields to store the unique identifier(s)/accession number(s) of records downloaded, such as the PubMed ID number (PMID). This allows subsequent linkage to the full database record and also facilitates information management such as duplicate detection and removal (i.e. de-duplication).

**Affiliation/address:** may include the institutional affiliation and/or email address of the author/investigator.

**Article identifier/digital object identifier (DOI):** can be used to cite and link to the full record. In PubMed, the Article Identifier (AID) field includes article identifiers submitted by journal publishers such as DOI (digital object identifier). In Ovid MEDLINE, the Digital Object Identifier (DO) field contains the DOI.

**Author identifier:** can be used to disambiguate authors with similar names. The identifier may be an ORCID (https://info.orcid.org/what-is-orcid), an International Standard Name Identifier (ISNI) https://isni.org/, or from the Virtual International Authority File (VIAF) https://viaf.org/.

**Clinical trial number:** if the record contains a clinical trial number, such as the registration number assigned by the ClinicalTrials.gov or ISRCTN schemes, or a number allocated by the sponsor of the trial, these should be downloaded to aid linking of trial reports to the original studies. In PubMed, the Secondary Source ID field [SI] contains information from secondary sources such as ClinicalTrials.gov and ISRCTN. Similarly, in Ovid MEDLINE, the Secondary Source Linking (SL) field contains the URL to ClinicalTrials.gov and ISRCTN resources where these are mentioned in MEDLINE records. In Embase, the Clinical Trial Number (CN) field contains clinical trial numbers associated with the record.

**Index terms/thesaurus terms/keywords:** These help indicate why records were retrieved if the title and abstract lack detail.
**Investigator name:** this field contains personal names of individuals (e.g. collaborators and investigators) who are not authors of the article but rather are listed in the article as members of a collective/corporate group that is an author of the article.

**Language:** this is the language (or languages) of publication of the original document.

**Location identifier:** in PubMed, this field includes the DOI or publisher ID that serves the role of pagination to locate an online article.

**Original title/Title:** if the original title of the document is not in English and both the original title and the translated title are available, then both titles should be downloaded into separate database fields, to aid correct identification of the reference and de-duplication. See also Transliterated title below with respect to PubMed.

**Other term:** in PubMed this field contains largely non-MeSH subject terms (also referred to as Keywords) that describe the content of the article. Author-supplied keywords are included here in PubMed (since 2013).

**Registry Number/EC Number and Substance Name:** these fields provide supplementary subject information regarding substances (chemicals, drugs and enzymes).

**Transliterated title:** in PubMed, this field contains the title of each item originally published in a non-English language, in that language. Transliterations of article titles in some Cyrillic languages (Greek, Bulgarian, Russian, Serbian and Ukrainian) were added to this field until 2004. This field can be useful for de-duplication.

**Comments, corrections, errata, retractions and updates:**

It is mandatory, for Cochrane Reviews of interventions, to examine any relevant retraction statements and errata for information (MECIR C48). All fields that relate to subsequently published comments, corrections, errata, retractions and updates should be selected for inclusion in the download, so that any impact of these subsequent publications can be taken into account. The MECIR standard specifies: “Care should be taken to ensure that this information is retrieved in all database searches by downloading the appropriate fields, together with the citation data”. For example, the most important fields to consider, in relation to comments, errata, retractions, etc., together with their field labels in PubMed, are provided in...
Box 4.a.
### Box 4.a Important field labels in PubMed in relation to comments, errata, retractions, etc.

<table>
<thead>
<tr>
<th>Field</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIN</td>
<td>‘Comment in’</td>
</tr>
<tr>
<td>CON</td>
<td>‘Comment on’</td>
</tr>
<tr>
<td>CRI</td>
<td>‘Corrected and Republished in’</td>
</tr>
<tr>
<td>CRF</td>
<td>‘Corrected and Republished from’</td>
</tr>
<tr>
<td>EIN</td>
<td>‘Erratum in’</td>
</tr>
<tr>
<td>EFR</td>
<td>‘Erratum for’</td>
</tr>
<tr>
<td>ECI</td>
<td>Expression of Concern in</td>
</tr>
<tr>
<td>ECF</td>
<td>Expression of Concern for</td>
</tr>
<tr>
<td>RIN</td>
<td>‘Retraction in’</td>
</tr>
<tr>
<td>ROF</td>
<td>‘Retraction of’</td>
</tr>
<tr>
<td>RRI</td>
<td>‘Retracted and Republished in’</td>
</tr>
<tr>
<td>RRF</td>
<td>‘Retracted and Republished from’</td>
</tr>
<tr>
<td>RPI</td>
<td>‘Republished in’</td>
</tr>
<tr>
<td>RPF</td>
<td>‘Republished from’</td>
</tr>
<tr>
<td>UIN</td>
<td>‘Update in’</td>
</tr>
<tr>
<td>UOF</td>
<td>‘Update of’</td>
</tr>
</tbody>
</table>

See:


The above list is provided as an example of the relevant fields in PubMed and as an indicator of the equivalent fields in other databases and service providers.
4.3 De-duplicating references

Because searching to inform systematic reviews is intended to be extensive, thousands of records may be retrieved from multiple sources. References to the same article (that is, exactly the same bibliographic reference) may be downloaded multiple times from different sources and duplicates can even be found within individual databases. The failure to remove duplicate records leads to extra time and effort during the screening phase and may lead to difficulty in specifying the total number of non-duplicate records in the PRISMA flow diagram (Page et al 2021a, Page et al 2021b). Failure to identify duplicate records may even lead to mistakenly including duplicate data in systematic reviews (Tramèr et al 1997). On the other hand, deleting non-duplicate records from search retrievals in error may lead to omitting relevant studies from systematic reviews. This is a particular concern in using simple filters for reducing retrieval of duplicate records during searching. For example, recent testing of the Exclude MEDLINE Journals filter in Embase suggests that this approach may result in loss of unique records (Premji and Ganshorn 2020). Many Cochrane Information Specialists de-duplicate records so that review authors see only search results that have already been de-duplicated.

Formatting of citation information often varies across sources, and automated identification of duplicate references from within reference management software may lead to false positives (removing non-duplicate records) and false negatives (retaining duplicate records). Meanwhile, de-duplication through visual examination of each record is time-consuming and often impractical. Several strategies have been developed to address these issues. Methods for modifying duplicate detection algorithms within reference management software have been developed and tested (Kwon et al 2015, Bramer et al 2016b). An online method to identify search results that are duplicates of PubMed citations has been reported (Sampson et al 2006). Comparisons of false positives, false negatives, and time involved in use of different searching methods and reference software for de-duplication have been tested, with no clear advantage to any one method (Kwon et al 2015). Both commercial deduplication programmes (Borissov et al 2022) and open-source software programs for online duplicate detection have also been developed (Wallace et al 2012, Jiang et al 2014, Rathbone et al 2015a, Rathbone et al 2015b, Hair et al 2021, Escaldelai et al 2022). Records may also be exported from reference management software into systematic review production software that provides automated duplicate detection (e.g. Covidence, Rayyan) and deduplicated there (Guimarães et al 2022). A recent comparison of several de-duplication approaches including the Ovid multifile search, reference management software, and systematic review production software has revealed that different methods have different combinations of false positives and false negatives, with systematic review production software being among the most accurate methods (McKeown and Mir 2021). When practical, manual methods may still be best, depending on the available alternatives. For example, a recent case study comparing manual and automated tools for completion of systematic review tasks found that manual duplicate detection performed better than automated detection (Clark et al 2021). There is no consensus on the optimal method for duplicate detection, and the most appropriate method will most likely depend upon the size of the combined dataset, the identity, number and output format of the
resources searched, access to software tools, and the skill and comfort level of the operator. A combination of automated methods and visual inspection is often used.

After de-duplication of search results, records may be screened for inclusion from within the reference management database, exported into dedicated screening software, or imported into systematic review production software (where further deduplication may take place). See Chapter 4, Section 4.6.6.1 for discussion of software to support the screening process. Records for included and excluded studies can be exported and uploaded into systematic review software such as RevMan. Instructions for importing references from reference management software into RevMan 5 can be found at https://community.cochrane.org/help/tools-and-software/revman-5/support-revman-5/revman-5-faq and directions for importing references into RevMan Web can be found at https://documentation.cochrane.org/revman-kb/import-references-for-included-and-excluded-studies-95422738.html.

4.4 Summary points

- Cochrane Review authors should seek advice from their Cochrane Information Specialist, or other medical/healthcare librarian or information specialist, on managing references.

- Authors of non-Cochrane reviews should seek advice from a medical/healthcare librarian or information specialist, with experience of managing references for systematic reviews.

- Use of reference management software is recommended.

- Ensure that all the necessary fields are downloaded.

- Remove duplicate references before screening.

- Either screen references within the reference management software and export references for the included and excluded studies into systematic review software, or export references to specialized screening software.

5 Supplement information

Authors: Carol Lefebvre, Julie Glanville, Simon Briscoe, Robin Featherstone, Anne Littlewood, Maria-Inti Metzendorf, Anna Noel-Storr, Robin Paynter, Tamara Rader, James Thomas and L. Susan Wieland on behalf of the Cochrane Information Retrieval Methods Group

6 Acknowledgements

This chapter has been developed from sections of previous editions of this Handbook co-authored since 1995 by Kay Dickersin, Julie Glanville, Kristen Larson, Carol Lefebvre, Eric Manheimer, Chris Marshall and Farhad Shokraneh. Many of the sources listed in this Technical Supplement, the accompanying Appendix and Chapter 4 of the Cochrane Handbook for
Systematic Reviews of Interventions have been brought to our attention by a variety of people over the years and we should like to acknowledge this. We should like to acknowledge: Ruth Foxlee, (formerly) Information Specialist, Cochrane Editorial Unit; Miranda Cumpston, (formerly) Head of Learning and Support, Cochrane Central Executive; Colleen Finley, Product Manager, John Wiley and Sons, for checking sections relating to searching the Cochrane Library; the (UK) National Institute for Health and Care Excellence and the German Institute for Quality and Efficiency in Health Care (IQWiG) for support in identifying some of the references; the (US) Agency for Healthcare Research and Quality (AHRQ) Effective Healthcare Program Scientific Resource Center Article Alert service; Tianjing Li, Co-Convenor, Comparing Multiple Interventions Methods Group, for text and references that formed the basis of the re-drafting of parts of the section on Selecting studies; Lesley Gillespie, Cochrane author and former Editor and Trials Search Co-ordinator of the Cochrane Bone, Joint and Muscle Trauma Group, for copy-editing an early draft; The Cochrane Information Specialist Executive, the Cochrane Information Specialists’ Support Team, Cochrane Information Specialists and members of the Cochrane Information Retrieval Methods Group for comments on drafts.

7 References


Almerie MQ, Matar H, Jones V. Searching the Polish Medical Bibliography (Polska Bibliografia Lekarska) for trials. Health Information and Libraries Journal 2007; 24: 283-286.


Balan PF, Gerits A, Vanduffel W. A practical application of text mining to literature on cognitive rehabilitation and enhancement through neurostimulation. Front Syst Neurosci 2014; 8: 182.


Booth A. Cochrane or cock-eyed? How should we conduct systematic reviews of qualitative research? Qualitative Evidence-based Practice Conference, Taking a Critical Stance; 2001; Coventry. [http://www.leeds.ac.uk/educol/documents/00001724.htm](http://www.leeds.ac.uk/educol/documents/00001724.htm).


Bramer WM. Variation in number of hits for complex searches in Google Scholar. *Journal of the Medical Library Association* 2016; **104**: 143-145.


Brand-de Heer DL. A comparison of the coverage of clinical medicine provided by PASCAL BIOMED and MEDLINE. *Health Information and Libraries Journal* 2001; **18**: 110-116.


Briscoe S, Cooper C. The British Nursing Index and CINAHL: a comparison of journal title coverage and the implications for information professionals. *Health Info Libr J* 2014; **31**: 195-203.


Briscoe S, Rogers M. An alternative screening approach for Google Search identifies an accurate and manageable number of results for a systematic review (case study). *Health Info Libr J* 2021.


Clark OAC, Castro AA, Atallah AN. Searching LILACS database improves systematic reviews. 6th Cochrane Colloquium; 1998; Baltimore (MD), USA. https://abstracts.cochrane.org/1998-baltimore/searching-lilacs-database-improves-systematic-reviews.


Cooper C, Lovell R, Husk K, Booth A, Garside R. Supplementary search methods were more effective and offered better value than bibliographic database searching: A case study from public health and environmental enhancement. *Res Synth Methods* 2017b; **9**: 195-223.


Cooper C, Court R, Kotas E, Schauburger U. A technical review of three clinical trials register resources indicates where improvements to the search interfaces are needed. *Research Synthesis Methods* 2021a; **12**: 384-393.


Crisan A, Munzner T, Gardy JL. Adjutant: an R-based tool to support topic discovery for systematic and literature reviews. *Bioinformatics* 2019; **35**: 1070-1072.

Curkovic M, Kosec A. Bubble effect: including internet search engines in systematic reviews introduces selection bias and impedes scientific reproducibility. *BMC Medical Research Methodology* 2018; **18**: 130.

Dal-Re R, Ross JS, Marusic A. Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. *J Clin Epidemiol* 2016; **75**: 100-107.
De Oliveira GS, Jr., Jung MJ, McCarthy RJ. Discrepancies between randomized controlled trial registry entries and content of corresponding manuscripts reported in anesthesiology journals. *Anesth Analg* 2015; **121**: 1030-1033.


Doshi P. FDA to begin releasing clinical study reports in pilot programme. *BMJ* 2018; **360**: k294.


Farace DJ, Frantzen J. Third International Conference on Grey Literature: Perspectives on the design and transfer of scientific and technical information; 1997; Luxembourg. Amsterdam: TransAtlantic; 1997.


Garfield E. The evolution of the Science Citation Index. *Int Microbiol* 2007; **10**: 65-69.

Glanville J, Lefebvre C. Identifying systematic reviews: key resources. *ACP Journal Club* 2000; **132**: A11-12.


Glanville J, Kotas E, Featherstone R, Dooley G. Which are the most sensitive search filters to identify randomized controlled trials in MEDLINE? *J Med Libr Assoc* 2020; **108**: 556-563.


Glanville JM, Duffy S, McCool R, Varley D. Searching ClinicalTrials.gov and the International Clinical Trials Registry Platform to inform systematic reviews: what are the optimal search approaches? *J Med Libr Assoc* 2014; **102**: 177-183.


Goldacre B, Turner E, on behalf of the OpenTrials team. You can now search FDA approval documents easily at fda.opentrials.net. *BMJ* 2017; **356**: j677.


Hartling L, Featherstone R, Nuspl M, Shave K, Dryden DM, Vandermeer B. Grey literature in systematic reviews: a cross-sectional study of the contribution of non-English reports, unpublished studies and dissertations to the results of meta-analyses in child-relevant reviews. *BMC Medical Research Methodology* 2017; 17: 64.

Harzing AW. Publish or Perish 2007. [https://harzing.com/resources/publish-or-perish](https://harzing.com/resources/publish-or-perish).


Hinde S, Spackman E. Bidirectional citation searching to completion: an exploration of literature searching methods. *Pharmacoeconomics* 2015; **33**: 5-11.


Horsley T, Dingwall O, Sampson M. Checking reference lists to find additional studies for systematic reviews. *Cochrane Database of Systematic Reviews* 2011; **8**: MR000026.


Jorgensen L, Gotzsche PC, Jefferson T. Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. *Syst Rev* 2018; 7: 8.


Lefebvre C, Eisinga A, McDonald S, Paul N. Enhancing access to reports of randomized trials published world-wide - the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in *The Cochrane Library. Emerg Themes Epidemiol* 2008; 5: 13.


Linder SK, Kamath GR, Pratt GF, Saraykar SS, Volk RJ. Citation searches are more sensitive than keyword searches to identify studies using specific measurement instruments. *J Clin Epidemiol* 2015; 68: 412-417.


Lunny C, McKenzie JE, McDonald S. Retrieval of overviews of systematic reviews in MEDLINE was improved by the development of an objectively derived and validated search strategy. *J Clin Epidemiol* 2015; 74: 107-118.


Manriquez JJ. Searching the LILACS database could improve systematic reviews in dermatology. *Archives of dermatology* 2009; 145: 947-948.

McDonald S. Improving access to the international coverage of reports of controlled trials in electronic databases: a search of the Australasian Medical Index. Health Info Libr J 2002; 19: 14-20.


McKeown S, Mir ZM. Considerations for conducting systematic reviews: evaluating the performance of different methods for de-duplicating references. Systematic reviews 2021; 10: 38.


Miron L, Gonçalves RS, Musen MA. Obstacles to the reuse of study metadata in ClinicalTrials.gov. Sci Data 2020; 7: 443.


Paez A. Gray literature: An important resource in systematic reviews. *J Evid Based Med* 2017; **10**: 233-240.

Page MJ, Shamseer L, Tricco AC. Registration of systematic reviews in PROSPERO: 30,000 records and counting. *Syst Rev* 2018; **7**: 32.


Richards D. Handsearching still a valuable element of the systematic review. *Evidence-Based Dentistry* 2008; *9*: 85.


Shokraneh F, Adams CE. Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis. *BioImpacts* 2017; **7**: 209-217.


Stansfield C, Dickson K, Bangpan M. Exploring issues in the conduct of website searching and other online sources for systematic reviews: how can we be systematic? *Syst Rev* 2016; 5: 191.


Urlings MJE, Duyx B, Swaen GMH, Bouter LM, Zeegers MP. Citation bias and other determinants of citation in biomedical research: findings from six citation networks. *J Clin Epidemiol* 2021; 132: 71-78.


Watson RJ, Richardson PH. Accessing the literature on outcome studies in group psychotherapy: the sensitivity and precision of Medline and PsycINFO bibliographic database searching. *BRITISH JOURNAL OF MEDICAL PSYCHOLOGY* 1999b; **72**: 127-134.


Wilczynski NL, Haynes RB, for the Hedges Team. EMBASE search strategies achieved high sensitivity and specificity for retrieving methodologically sound systematic reviews. *J Clin Epidemiol* 2007; **60**: 29-33.

Wilczynski NL, McKibbon KA, Haynes RB. Sensitive Clinical Queries retrieved relevant systematic reviews as well as primary studies: an analytic survey. *J Clin Epidemiol* 2011; **64**: 1341-1349.


Xue J, Chen W, Chen L, Gaudet L, Moher D, Walker M, Wen SW. Significant discrepancies were found in pooled estimates of searching with Chinese indexes versus searching with English indexes. *J Clin Epidemiol* 2016; **70**: 246-253.

